<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0"
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main" xml:id="_rasejAv">Patient-Reported Outcome Measures for Health-Related Quality of Life in Patients With Psoriasis A Systematic Review</title>
				<funder>
					<orgName type="full">Pfizer</orgName>
					<idno type="DOI" subtype="crossref">https://doi.org/10.13039/100004319</idno>
				</funder>
				<funder>
					<orgName type="full">UCB</orgName>
					<idno type="DOI" subtype="crossref">https://doi.org/10.13039/100011110</idno>
				</funder>
				<funder>
					<orgName type="full">National Psoriasis Foundation</orgName>
					<orgName type="abbreviated">NPF</orgName>
					<idno type="DOI" subtype="crossref">https://doi.org/10.13039/100003185</idno>
				</funder>
				<funder>
					<orgName type="full">Regeneron</orgName>
				</funder>
				<funder>
					<orgName type="full">Boehringer Ingelheim</orgName>
					<idno type="DOI" subtype="crossref">https://doi.org/10.13039/100008349</idno>
				</funder>
				<funder>
					<orgName type="full">International Dermatology Outcome Measures (IDEOM)</orgName>
				</funder>
				<funder>
					<orgName type="full">Sanofi Genzyme</orgName>
					<idno type="DOI" subtype="crossref">https://doi.org/10.13039/100013995</idno>
				</funder>
				<funder>
					<orgName type="full">AbbVie</orgName>
					<idno type="DOI" subtype="crossref">https://doi.org/10.13039/100006483</idno>
				</funder>
				<funder>
					<orgName type="full">International Dermatology Outcome Measures</orgName>
				</funder>
				<funder>
					<orgName type="full">Alpine Immune Sciences</orgName>
				</funder>
				<funder ref="#_AKAsahp">
					<orgName type="full">US National Institute of Arthritis and Musculoskeletal and Skin Diseases of the US National Institutes of Health</orgName>
				</funder>
				<funder>
					<orgName type="full">AstraZeneca</orgName>
					<idno type="DOI" subtype="crossref">https://doi.org/10.13039/100004325</idno>
				</funder>
				<funder>
					<orgName type="full">Sun Pharma</orgName>
					<idno type="DOI" subtype="crossref">https://doi.org/10.13039/501100013671</idno>
				</funder>
				<funder>
					<orgName type="full">Group for Research and Assessment of Psoriasis and Psoriatic Arthritis</orgName>
				</funder>
				<funder>
					<orgName type="full">Bayer</orgName>
					<idno type="DOI" subtype="crossref">https://doi.org/10.13039/100004326</idno>
				</funder>
				<funder>
					<orgName type="full">Amgen</orgName>
					<idno type="DOI" subtype="crossref">https://doi.org/10.13039/100002429</idno>
				</funder>
				<funder>
					<orgName type="full">BMS</orgName>
				</funder>
				<funder ref="#_dJcf7nd">
					<orgName type="full">unknown</orgName>
				</funder>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability  status="unknown">
					<licence/>
					<p type="raw">© 2024 American Medical Association. All rights reserved. Downloaded from jamanetwork.com by Leiden University Libraries user on 04/30/2024 © 2024 American Medical Association. All rights reserved. Downloaded from jamanetwork.com by Leiden University Libraries user on 04/30/2024 © 2024 American Medical Association. All rights reserved. Downloaded from jamanetwork.com by Leiden University Libraries user on 04/30/2024 © 2024 American Medical Association. All rights reserved. Downloaded from jamanetwork.com by Leiden University Libraries user on 04/30/2024</p>
				</availability>
				<date type="published" when="2024-01-24">January 24, 2024.</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><roleName>MD, MMSc</roleName><forename type="first">Lourdes</forename><forename type="middle">M</forename><surname>Pérez-Chada</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Zachary</forename><forename type="middle">H</forename><surname>Hopkins</surname></persName>
						</author>
						<author>
							<persName><forename type="first">;</forename><surname>Deepak</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">M</forename><forename type="middle">W</forename><surname>Balak</surname></persName>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">Sarem</forename><surname>Rashid</surname></persName>
						</author>
						<author>
							<persName><roleName>BS</roleName><forename type="first">Andrew</forename><surname>Creadore</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Brian</forename><surname>Chu</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Camila</forename><surname>Villa</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Michael</forename><forename type="middle">J</forename><surname>Woodbury</surname></persName>
						</author>
						<author>
							<persName><roleName>BS</roleName><forename type="first">April</forename><forename type="middle">W</forename><surname>Armstrong</surname></persName>
						</author>
						<author>
							<persName><roleName>MD, MPH</roleName><forename type="first">Vibeke</forename><surname>Strand</surname></persName>
						</author>
						<author>
							<persName><roleName>MD</roleName><forename type="first">Alice</forename><forename type="middle">B</forename><surname>Gottlieb</surname></persName>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">Joseph</forename><forename type="middle">F</forename><surname>Merola</surname></persName>
						</author>
						<author>
							<persName><roleName>MD, MMSc;</roleName><forename type="first">John</forename><forename type="middle">S</forename><surname>Barbieri</surname></persName>
						</author>
						<author role="corresp">
							<persName><roleName>MD, MMSc</roleName><forename type="first">Lourdes</forename><forename type="middle">M</forename><surname>Perez-Chada</surname></persName>
							<email>lperezchada@bwh.harvard.edu</email>
						</author>
						<author>
							<persName><surname>Pérez-Chada</surname></persName>
						</author>
						<author>
							<persName><surname>Creadore</surname></persName>
						</author>
						<author>
							<persName><surname>Villa</surname></persName>
						</author>
						<author>
							<persName><roleName>Creadore</roleName><forename type="first">Pérez-Chada</forename><surname>Rashid</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Villa-Ruiz</forename><surname>Gottlieb</surname></persName>
						</author>
						<author>
							<persName><roleName>Balak, Rashid</roleName><forename type="first">Pérez-Chada</forename><surname>Hopkins</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Villa-Ruiz</forename><surname>Woodbury</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Villa-Ruiz</forename><surname>Rashid</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Pérez</forename><forename type="middle">-</forename><surname>Chada</surname></persName>
						</author>
						<author>
							<affiliation key="aff0">
								<note type="raw_affiliation">Department of Dermatology , Brigham and Women&apos;s Hospital , 41 Ave Louis Pasteur , 313 , Boston , MA 02115</note>
								<orgName type="department" key="dep1">Department of Dermatology</orgName>
								<orgName type="department" key="dep2">Brigham and Women&apos;s Hospital</orgName>
								<address>
									<addrLine>41 Ave Louis Pasteur 313</addrLine>
									<postCode>02115</postCode>
									<settlement>Boston</settlement>
									<region>MA</region>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff1">
								<note type="raw_affiliation">Department of Dermatology , Brigham and Women&apos;s Hospital , Boston , Massachusetts Woodbury , Barbieri );</note>
								<orgName type="department">Department of Dermatology</orgName>
								<orgName type="institution">Brigham and Women&apos;s Hospital</orgName>
								<address>
									<settlement>Boston Woodbury Barbieri</settlement>
									<region>Massachusetts</region>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff2">
								<note type="raw_affiliation">Department of Dermatology , University of Utah , Salt Lake City (Hopkins );</note>
								<orgName type="department">Department of Dermatology</orgName>
								<orgName type="institution">University of Utah</orgName>
								<address>
									<settlement>Salt Lake City (Hopkins</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff3">
								<note type="raw_affiliation">Department of Dermatology , Leiden University Medical Center , Leiden , the Netherlands (</note>
								<orgName type="department">Department of Dermatology</orgName>
								<orgName type="institution">Leiden University Medical Center</orgName>
								<address>
									<settlement>Leiden</settlement>
									<country key="NL">the Netherlands</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff4">
								<note type="raw_affiliation">Balak) ; Department of Dermatology , Boston University Chobanian &amp; Avedisian School of Medicine , Boston , Massachusetts ( Rashid );</note>
								<orgName type="department" key="dep1">Balak)</orgName>
								<orgName type="department" key="dep2">Department of Dermatology</orgName>
								<orgName type="laboratory">Rashid</orgName>
								<orgName type="institution">Boston University Chobanian &amp; Avedisian School of Medicine</orgName>
								<address>
									<settlement>Boston</settlement>
									<region>Massachusetts</region>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff5">
								<note type="raw_affiliation">Department of Dermatology , Perelman School of Medicine , University of Pennsylvania , Philadelphia (Chu) ;</note>
								<orgName type="department" key="dep1">Department of Dermatology</orgName>
								<orgName type="department" key="dep2">Perelman School of Medicine</orgName>
								<orgName type="institution">University of Pennsylvania</orgName>
								<address>
									<settlement>Philadelphia (Chu</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff6">
								<note type="raw_affiliation">Department of Dermatology , University of California , Los Angeles , Los Angeles (Armstrong) ;</note>
								<orgName type="department">Department of Dermatology</orgName>
								<orgName type="institution">University of California</orgName>
								<address>
									<settlement>Los Angeles Los Angeles (Armstrong</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff7">
								<note type="raw_affiliation">Division of Immunology and Rheumatology , Stanford University School of Medicine , Palo Alto , California</note>
								<orgName type="department">Division of Immunology and Rheumatology</orgName>
								<orgName type="institution">Stanford University School of Medicine</orgName>
								<address>
									<settlement>Palo Alto</settlement>
									<region>California</region>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff8">
								<note type="raw_affiliation">Department of Dermatology , Icahn School of Medicine at Mt Sinai , New York , New York (Gottlieb) ;</note>
								<orgName type="department">Department of Dermatology</orgName>
								<orgName type="institution">Icahn School of Medicine at Mt Sinai</orgName>
								<address>
									<settlement>New York</settlement>
									<region>New York (Gottlieb</region>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff9">
								<note type="raw_affiliation">Division of Rheumatology , Department of Dermatology and Medicine , Brigham and Women&apos;s Hospital , Boston , Massachusetts</note>
								<orgName type="department" key="dep1">Division of Rheumatology</orgName>
								<orgName type="department" key="dep2">Department of Dermatology and Medicine</orgName>
								<orgName type="institution">Brigham and Women&apos;s Hospital</orgName>
								<address>
									<settlement>Boston</settlement>
									<region>Massachusetts</region>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff10">
								<note type="raw_affiliation">Hopkins , Strand , Gottlieb. Ermium ,</note>
								<orgName type="department">Ermium</orgName>
								<orgName type="institution">Hopkins</orgName>
								<address>
									<settlement>Strand</settlement>
									<country>Gottlieb</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff11">
								<note type="raw_affiliation">GlaxoSmithKline , Inmedix , Novartis , Pfizer , R-Pharm , Sandoz , Sanofi , Setpoint , Sorrento ,</note>
								<orgName type="department">R-Pharm</orgName>
								<orgName type="laboratory">Inmedix</orgName>
								<orgName type="institution" key="instit1">GlaxoSmithKline</orgName>
								<orgName type="institution" key="instit2">Novartis</orgName>
								<orgName type="institution" key="instit3">Pfizer</orgName>
								<orgName type="institution" key="instit4">Sandoz</orgName>
								<orgName type="institution" key="instit5">Sanofi</orgName>
								<orgName type="institution" key="instit6">Setpoint</orgName>
								<address>
									<settlement>Sorrento</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff12">
								<note type="raw_affiliation">Spherix , Scipher , UCB , Avotres Therapeutics ,</note>
								<orgName type="department">Avotres Therapeutics</orgName>
								<orgName type="laboratory">Spherix</orgName>
								<orgName type="institution">UCB</orgName>
								<address>
									<region>Scipher</region>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff13">
								<note type="raw_affiliation">Boehringer Ingelheim , Bristol Myers Squibb , Dice Therapeutics , Highlight Therapeutics , Eli Lilly , Janssen , Novartis , Sanofi , UCB, and XBiotech ; research/educational grants from AnaptysBio , Highlight Therapeutics , Moonlake Immunotherapeutics AG , Novartis , Bristol Myers Squibb , and UCB Pharma ,</note>
								<orgName type="department" key="dep1">Highlight Therapeutics</orgName>
								<orgName type="department" key="dep2">research/educational grants from AnaptysBio</orgName>
								<orgName type="department" key="dep3">Highlight Therapeutics</orgName>
								<orgName type="department" key="dep4">Moonlake Immunotherapeutics AG</orgName>
								<orgName type="laboratory" key="lab1">Dice Therapeutics</orgName>
								<orgName type="laboratory" key="lab2">Janssen</orgName>
								<orgName type="institution" key="instit1">Boehringer Ingelheim</orgName>
								<orgName type="institution" key="instit2">Bristol Myers Squibb</orgName>
								<orgName type="institution" key="instit3">Eli Lilly</orgName>
								<orgName type="institution" key="instit4">Novartis</orgName>
								<orgName type="institution" key="instit5">Sanofi</orgName>
								<orgName type="institution" key="instit6">UCB, and XBiotech</orgName>
								<orgName type="institution" key="instit7">Novartis</orgName>
								<orgName type="institution" key="instit8">Bristol Myers Squibb</orgName>
								<orgName type="institution" key="instit9">UCB Pharma</orgName>
							</affiliation>
						</author>
						<title level="a" type="main" xml:id="_Ny7YNAp">Patient-Reported Outcome Measures for Health-Related Quality of Life in Patients With Psoriasis A Systematic Review</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2024-01-24">January 24, 2024.</date>
						</imprint>
					</monogr>
					<idno type="MD5">5F597796CA25151940113C401BD94641</idno>
					<idno type="DOI">10.1001/jamadermatol.2023.5439</idno>
					<note type="submission">Accepted for Publication: November 3, 2023. fees from Modernizing Medicine, research funding and scientific</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.8.2" ident="GROBID" when="2025-08-31T10:18+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<label type="revision">a91ee48</label>
					<label type="parameters">startPage=-1, endPage=-1, consolidateCitations=2, consolidateHeader=2, consolidateFunders=1, includeRawAffiliations=true, includeRawCitations=true, includeRawCopyrights=true, generateTeiIds=true, generateTeiCoordinates=[all], sentenceSegmentation=true, flavor=null</label>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_Y2f9s2H">IMPORTANCE</head><p xml:id="_wqVuuCr"><s xml:id="_XTCF6r3">Multiple patient-reported outcome measures (PROMs) for health-related quality of life (HRQL) exist for patients with psoriasis.</s><s xml:id="_JRkH7VT">Evidence for the content validity and other measurement properties of these PROMs is critical to determine which HRQL PROMs could be recommended for use.</s><s xml:id="_z8Q6FSK">OBJECTIVE To systematically review the validity of HRQL-focused PROMs used in patients with psoriasis.</s></p><p xml:id="_aquvvhk"><s xml:id="_mWc2JRF">EVIDENCE REVIEW Using PubMed and Embase, full-text articles published in English or Spanish on development or validation studies for psoriasis-specific, dermatology-specific, or generic HRQL PROMs were included.</s><s xml:id="_e3rkQp9">Development studies included original development studies, even if not studied in psoriasis patients per Consensus-Based Standards for the Selection of Health Measurement Instruments (COSMIN) recommendations.</s><s xml:id="_8qKN7bv">If a study included multiple diagnoses, more than 50% of patients had to have psoriasis or psoriasis-specific subgroup analyses available.</s><s xml:id="_whBYxFA">Data extraction and analysis followed the COSMIN guidelines.</s><s xml:id="_PPC8Vmd">Two independent reviewers extracted and analyzed the data, including PROM characteristics, quality of measurement properties (structural validity, internal consistency, cross-cultural validity, reliability, measurement error, criterion validity, construct validity, and responsiveness), and level of evidence.</s><s xml:id="_3ZqucNq">PROMs were classified into 3 levels of recommendations: (1) PROM recommended for use; (2) PROM requires further validation; and (3) PROM not recommended for use.</s></p><p xml:id="_ne29Q6m"><s xml:id="_tMJJUc2">FINDINGS Overall, 97 articles were identified for extraction.</s><s xml:id="_ueq3ZuW">This included 19 psoriasis-specific, 8 skin-specific, and 6 generic PROMs.</s><s xml:id="_h9MSh3v">According to COSMIN standards, most measures identified received a B recommendation for use, indicating their potential but requiring further validation.</s><s xml:id="_skAVeT8">Only the Rasch reduced version of the Impact of Psoriasis Questionnaire (IPSO-11 Rasch) received an A recommendation for use given that it had sufficient content validity, structural validity, and internal consistency.</s></p><p xml:id="_VmxKRdw"><s xml:id="_T5RmKxb">CONCLUSIONS AND RELEVANCE This study identified a significant lack of information concerning the quality of HRQL measures in psoriasis.</s><s xml:id="_SmCm5WQ">This gap in knowledge can be attributed to the fact that traditional measures were developed using validation criteria that differ from the current standards in use.</s><s xml:id="_Ynf6fJ5">Consequently, additional validation studies in accordance with contemporary standards will be useful in aiding researchers and clinicians in determining the most suitable measure for assessing HRQL in patients with psoriasis.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<facsimile>
		<surface n="1" ulx="0.0" uly="0.0" lrx="611.865" lry="791.825"/>
		<surface n="2" ulx="0.0" uly="0.0" lrx="612.0" lry="792.0"/>
		<surface n="3" ulx="0.0" uly="0.0" lrx="612.0" lry="792.0"/>
		<surface n="4" ulx="0.0" uly="0.0" lrx="612.0" lry="792.0"/>
		<surface n="5" ulx="0.0" uly="0.0" lrx="612.0" lry="792.0"/>
		<surface n="6" ulx="0.0" uly="0.0" lrx="612.0" lry="792.0"/>
		<surface n="7" ulx="0.0" uly="0.0" lrx="612.0" lry="792.0"/>
		<surface n="8" ulx="0.0" uly="0.0" lrx="612.0" lry="792.0"/>
		<surface n="9" ulx="0.0" uly="0.0" lrx="612.0" lry="792.0"/>
		<surface n="10" ulx="0.0" uly="0.0" lrx="612.0" lry="792.0"/>
		<surface n="11" ulx="0.0" uly="0.0" lrx="612.0" lry="792.0"/>
		<surface n="12" ulx="0.0" uly="0.0" lrx="612.0" lry="792.0"/>
		<surface n="13" ulx="0.0" uly="0.0" lrx="612.0" lry="792.0"/>
		<surface n="14" ulx="0.0" uly="0.0" lrx="612.0" lry="792.0"/>
		<surface n="15" ulx="0.0" uly="0.0" lrx="612.0" lry="792.0"/>
	</facsimile>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0" xml:id="_g489Z4t"><p xml:id="_ADJf4FD"><s xml:id="_y9r6pcK">T he International Dermatology Outcome Measures (IDEOM) initiative is developing a Core Outcome Set for use in psoriasis clinical trials and longitudinal observational studies.</s><s xml:id="_wsSWMus">This process consists of 2 consecutive steps: (1) identifying a core set of domains and (2) selecting the most appropriate instrument to measure these domains. <ref type="bibr" target="#b0">1</ref> Selecting the right outcomes and valid measures for each domain is of paramount importance in the planning of clinical trials, as it enables direct comparison of interventions. <ref type="bibr" target="#b0">1</ref> It is also important that the selected outcomes hold significance for key stakeholders, including patients and clinicians.</s></p><p xml:id="_fsZpP5d"><s xml:id="_cTG2JZj">In 2018, IDEOM published a core domain set for psoriasis clinical trials and is now working on selecting instruments for identified domains.</s><s xml:id="_Ppjgksc">The domains included in the set consist of skin manifestations, psoriasis, and psoriatic arthritis (PsA) symptoms, investigator global, patient global, treatment satisfaction, and healthrelated quality of life (HRQL). <ref type="bibr" target="#b1">2</ref></s><s xml:id="_sebkEMG">RQL is a complex and multidimensional construct that captures individuals' quality of life relative to their health or disease status. <ref type="bibr" target="#b2">3,</ref><ref type="bibr" target="#b3">4</ref></s><s xml:id="_TfPCDZv">Wilson and Cleary 5 have developed one of the most frequently used conceptual models of HRQL.</s><s xml:id="_p5tUnhx">This model describes 5 levels of outcomes including biological and physiological factors, symptoms, functioning, general health perceptions, and overall quality of life.</s><s xml:id="_KhUcAE4">In this review, we defined HRQL as symptoms (physical or mental), physical functioning, social functioning (ie, interpersonal interactions/activities), role functioning (ie, academic/work achievement), and overall quality of life.</s></p><p xml:id="_sut4wE6"><s xml:id="_gF6kCZU">Psoriasis exerts a significant effect on a patient's HRQL. <ref type="bibr" target="#b5">[6]</ref><ref type="bibr" target="#b6">[7]</ref></s><s xml:id="_AFR8sek">]<ref type="bibr" target="#b7">[8]</ref><ref type="bibr" target="#b8">[9]</ref><ref type="bibr" target="#b9">[10]</ref><ref type="bibr" target="#b10">[11]</ref> Understanding a patient's current HRQL status is critical to support optimal disease management, informing patient-physician discussions, and delivering high-quality care. <ref type="bibr" target="#b2">3,</ref><ref type="bibr" target="#b7">8,</ref><ref type="bibr" target="#b9">[10]</ref><ref type="bibr" target="#b10">[11]</ref></s><s xml:id="_Y4XHDbb">1]<ref type="bibr" target="#b11">[12]</ref><ref type="bibr" target="#b12">[13]</ref><ref type="bibr" target="#b13">[14]</ref> Accordingly, multiple treatment guidelines have recommended HRQL measurement during routine psoriasis care. <ref type="bibr" target="#b14">[15]</ref><ref type="bibr" target="#b15">[16]</ref></s><s xml:id="_aVajxe5">]<ref type="bibr" target="#b16">[17]</ref><ref type="bibr" target="#b17">[18]</ref> To date, numerous psoriasis-specific, dermatology-or skinrelated quality of life (SRQL), and generic patient-reported outcome measures (PROMs) have been used to measure HRQL in patients with psoriasis.</s><s xml:id="_kK9gCaY">However, little is known about which of these measures might be most appropriate to evaluate HRQL among patients with psoriasis.</s><s xml:id="_H7vzdXg">To establish which HRQL PROMs are best validated and guide future validation efforts, we sought to systematically review and assess the measurement properties of HRQL PROMs used in psoriasis in accordance with the Consensus-Based Standards for the Selection of Health Measurement Instruments (COS-MIN) guidelines. <ref type="bibr" target="#b18">[19]</ref><ref type="bibr" target="#b19">[20]</ref></s><s xml:id="_yrRp5Cf"><ref type="bibr" target="#b20">[21]</ref></s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_p2JfN7u">Methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_9nWdzXQ">Protocol and Registration</head><p xml:id="_YAJMM9r"><s xml:id="_yXVKVYd">Th e r e v i e w p r o t o c o l wa s r e g i st e r e d o n P R O S P E R O (CRD42017075580).</s><s xml:id="_susyGTg">This study did not require ethics approval.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_McmqavG">Literature Search</head><p xml:id="_gM58PgS"><s xml:id="_Y5gXgHR">This review followed the COSMIN guideline for conducting systematic reviews of PROMs. <ref type="bibr" target="#b18">19</ref></s><s xml:id="_xUnFSb6">PubMed and Embase (OVID) databases were used (eMethods 1 in the Supplement).</s><s xml:id="_nXhXbv3">The overall search strategy aimed to (1) identify all PROMs used for HRQL in psoriasis (stage 1) and (2) identify development and validation studies for these identified PROMs (stage 2).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_f7kJtuQ">Study Selection</head><p xml:id="_rYrvSHJ"><s xml:id="_eMGgkSW">Abstract screening was conducted in Covidence by 2 independent reviewers.</s><s xml:id="_yfHdKf3">In cases of disagreement, the full-text article was retrieved and screened.</s><s xml:id="_ktMgpWQ">Full-text screening and data extraction was performed by 2 independent reviewers (L.M.P.-C., J.S.B., and/or Z.H.H.).</s><s xml:id="_wT4hqpt">In cases of disagreement, the reviewers discussed the case, and if needed, a third reviewer was queried.</s></p><p xml:id="_wW533cp"><s xml:id="_dETcdcS">We included any full-text article published in English or Spanish that investigated development or evaluation of measurement properties for a PROM assessing HRQL in patients with psoriasis.</s><s xml:id="_h6ANB22">In studies investigating multiple dermatologic conditions, psoriasis had to be present in 50% or more of the patients, or subgroup analyses on psoriasis-specific data had to be available.</s><s xml:id="_MFVEN5h">In addition, studies were required to report on a PROM that aimed to measure HRQL.</s><s xml:id="_tGuSHzx">Only multidimensional instruments that assessed 2 or more aspects of HRQL per the Wilson and Cleary model were included.</s><s xml:id="_rXcZqCW">PROMs that measured only 1 aspect of HRQL (eg, only mental health or work productivity) were excluded.</s></p><p xml:id="_xMDS6R9"><s xml:id="_WnYTZxk">Study population could include children, adolescents, or adults.</s><s xml:id="_ScWhy5Y">Developmentstudiescouldincludeoriginaldevelopmentstudies,even if not studied in psoriasis patients per COSMIN recommendations. <ref type="bibr" target="#b18">[19]</ref><ref type="bibr" target="#b19">[20]</ref></s><s xml:id="_zPeTvdJ">]<ref type="bibr" target="#b20">[21]</ref> Studies that only used the PROM as an outcome measurement or where PROMs were included only to validate a new PROM or other PROMs were excluded.</s><s xml:id="_qhkUBZc">PROMs tested among patients with PsA only were excluded.</s><s xml:id="_WgwDkFW">Psoriasis-specific instruments were defined as those developed for use only among patients with psoriasis and measuring psoriasis-related HRQL status.</s><s xml:id="_QaeMD5e">SRQL instruments were defined as instruments that were developed in patients with dermatologic conditions to measure cutaneous disease-mediated HRQL.</s><s xml:id="_9tfb5TR">General HRQL instruments were considered those that were developed for use in patients with any variety of medical conditions and were not specific to any 1 condition or organ system.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_w5VZtJN">Risk of Bias</head><p xml:id="_3AJ2TTb"><s xml:id="_pwvg4tz">The methodological quality of the included studies was evaluated using the COSMIN Risk of Bias checklist. <ref type="bibr" target="#b19">20,</ref><ref type="bibr" target="#b20">21</ref></s><s xml:id="_VZn7Ns8">Each study could be rated as very good, adequate, doubtful, or inadequate.</s><s xml:id="_3K6Ts9n">Disagreements were discussed until consensus was reached.</s><s xml:id="_r8Vx4V7">For structural validity and internal consistency, the instruments' measurement model (reflective vs formative) was considered.</s><s xml:id="_mrQU3qx">Reflective scales reflect the latent construct, ie, changes in HRQL caused changes in the</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_cmpCAGP">Key Points</head><p xml:id="_QtMjurf"><s xml:id="_vweuWKx">Question What are the measurement properties of existing patient-reported outcome measures that assess health-related quality of life in patients with psoriasis?</s><s xml:id="_9jjKtAw">Findings In this systematic review, almost all health-related quality of life measures for psoriasis were missing evidence for key measurement properties according to Consensus-Based Standards for the Selection of Health Measurement Instruments Guidelines; this gap in knowledge may arise from the fact that most of these measures, including those used routinely for registration trials, were developed using validation criteria that differ from the current standards in use.</s></p><p xml:id="_4BDbhk5"><s xml:id="_QEbZNYH">Meaning Further work is needed to demonstrate the validity, reliability, and responsiveness of other health-related quality measures in patients with psoriasis.</s><s xml:id="_haqCuzu">item scores measured.</s><s xml:id="_sM4sZQZ">Formative (sometimes called "causal") models measure items that directly cause changes in HRQL. <ref type="bibr" target="#b21">22</ref></s><s xml:id="_QVbPpvf">We characterized each instrument's original description as reflective or formative.</s><s xml:id="_RsAt3Ye">However, when a description was not available, this determination was made by the authors using guidance such as the thought test. <ref type="bibr" target="#b22">23</ref></s><s xml:id="_4BH57kK">Structural validity and internal consistency were not evaluated for formative instruments. <ref type="bibr" target="#b21">[22]</ref><ref type="bibr" target="#b22">[23]</ref></s><s xml:id="_nbb9xhm">3]<ref type="bibr" target="#b23">[24]</ref> If the instrument contained a mix of reflective and formative items and structural validity and internal consistency were reported, the instrument was assumed to be based on a reflective model and such measurement properties were evaluated. <ref type="bibr" target="#b19">20</ref></s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_aP9bfue">Evaluation of Measurement Properties</head><p xml:id="_7X6EyPa"><s xml:id="_bvusE6k">We assessed the following properties for each PROM development or validation study: content validity, internal consistency, structural validity, construct validity, cross-cultural validity, reliability, measurement error, and responsiveness. <ref type="bibr" target="#b19">20</ref></s><s xml:id="_e92h2Mn">Spanish translation, if required, was performed by 2 coauthors (J.S.B. or L.M.P-C.).</s><s xml:id="_9PgUQHB">PROM versions in specific languages were considered separate PROMs for data extraction and analysis.</s></p><p xml:id="_6cHQzU4"><s xml:id="_VuNeKEX">The results of each study on a measurement property were extracted and evaluated using the Criteria for Good Measurement Properties.</s><s xml:id="_PAyfabx">Accordingly, each result was rated as sufficient, insufficient, or indeterminate. <ref type="bibr" target="#b18">19</ref></s><s xml:id="_myKTpAn">Results from individual studies were then qualitatively summarized by measurement property per PROM.</s><s xml:id="_T3rUxna">The summarized result was also compared against the same criteria and rated as sufficient, insufficient, indeterminate, or inconsistent.</s><s xml:id="_udMmUCY">For hypothesis-based construct validity testing, the acceptable degree of correlation between PROMs was established a priori (eMethods 2 in the Supplement).</s><s xml:id="_rXVctqj">Relatedly, hypothesis testing comparisons should be guided by the quality of the comparator.</s><s xml:id="_dxEdk8M">For details on comparator quality assessment and definitions see eMethods 3 in the Supplement.</s></p><p xml:id="_RFcTEXR"><s xml:id="_59tmeJW">To assess the comprehensiveness of PROMs, we established a priori a minimum set of domains that should be assessed by a given PROM to receive a positive rating for comprehensiveness.</s><s xml:id="_s39zRAr">We defined the minimum set of required domains based on the HRQL model proposed by Wilson and Cleary, the most frequently used conceptual model of HRQL. <ref type="bibr" target="#b4">5</ref> Accordingly, the comprehensiveness of a PROM would be rated positive if it included at least 1 item for the following domains: symptoms, physical functioning, social functioning (ie, interpersonal interactions/activities), role functioning (ie, academic/work achievement), depression or anxiety, and body image.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_3wvXf4m">Grading the Quality of Evidence</head><p xml:id="_wdba9ue"><s xml:id="_QNkNPsj">The quality of evidence for the summary score of each PROM was rated as high, moderate, low, or very low according to modified GRADE guidelines. <ref type="bibr" target="#b18">19,</ref><ref type="bibr" target="#b19">20</ref></s><s xml:id="_etxbKKg">These ratings are based on 4 factors: risk of bias (ie, quality of the studies), consistency of results from studies, directness (different populations, interventions, or outcomes than those of interest to the review), and precision (width of confidence intervals).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_jYn4rs2">Recommendation For Use of PROMs in Psoriasis</head><p xml:id="_krdkYpg"><s xml:id="_BvJj8pG">Each PROM was assigned to 1 of the 3 standardized COSMIN recommendations for use categories. <ref type="bibr" target="#b18">19</ref></s><s xml:id="_4KqUn8z">Category A: the PROM can be rec-</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_UUJXyQ3">Results</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_tQvtZQD">Study Selection</head><p xml:id="_xAZHewp"><s xml:id="_EC6Btyp">A systematic literature review was performed on March 23, 2023.</s><s xml:id="_Wvb7Zdd">We identified 2396 abstracts; after removing duplicates, 1966 abstracts remained for screening.</s><s xml:id="_RkseH8R">After screening, 80 full-text studies were identified and an additional 17 studies were added after searching references (Figure <ref type="figure">1</ref>).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_qnVFa5q">Study Characteristics</head><p xml:id="_dJygP4P"><s xml:id="_QKJgB3M">We identified 19 psoriasis-specific PROMs, 8 SRQL, and 6 generic PROMs that were developed and/or validated in psoriasis (Table <ref type="table" target="#tab_0">1</ref>  <ref type="bibr" target="#b39">40,</ref><ref type="bibr" target="#b42">[43]</ref><ref type="bibr" target="#b43">[44]</ref><ref type="bibr" target="#b44">[45]</ref><ref type="bibr" target="#b45">[46]</ref><ref type="bibr" target="#b46">[47]</ref><ref type="bibr" target="#b47">[48]</ref><ref type="bibr" target="#b65">66,</ref><ref type="bibr" target="#b71">72,</ref><ref type="bibr">78,</ref><ref type="bibr">86,</ref><ref type="bibr">92,</ref><ref type="bibr">95,</ref><ref type="bibr">104,</ref><ref type="bibr">109,</ref><ref type="bibr">110</ref> and Table <ref type="table" target="#tab_3">2</ref> 41, 42, 57, 67, 85, 91, 93,94,96,97,108,131-133</s></p><p xml:id="_aTgjZSa"><s xml:id="_EZscn4R">).</s><s xml:id="_96cZeXQ">All measures were self-reported except for the Psodisk, which is designed to be used during the patient visit together with the clinician.</s><s xml:id="_SeCPUT4">Most measures were developed and scaled using classical test theory (CTT) except the IPSO-11 Rasch and the Skindex-17, which used Rasch methods and Item Response Theory.</s><s xml:id="_KKCA3Pu">Most measures were multidomain and used an adjectival scale (Table <ref type="table" target="#tab_0">1</ref>).</s><s xml:id="_ZkYyMg7">All PROMs were multi-item instruments.</s></p><p xml:id="_txRsHhP"><s xml:id="_TzadYKq">Among psoriasis-specific PROMs, most measures addressed psoriasis vulgaris, except the IPBOD (inverse psoriasis), <ref type="bibr">92</ref> the Nail Psoriasis Quality of Life Scale (NPQ10), <ref type="bibr" target="#b44">45</ref> and the Nail Assessment in Psoriasis and Psoriatic Arthritis Quality of Life (NAPPAQOL) <ref type="bibr" target="#b71">72</ref> scales (nail psoriasis).</s><s xml:id="_eCxuCYZ">All instruments were developed using adult patients with psoriasis except the NPQ10, which included children and adolescents. <ref type="bibr" target="#b44">45</ref></s><s xml:id="_Gyu8c4k">HRQL was generally represented by emotional effect, role functioning, social functioning, disease signs, and symptoms.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_MMNTNr7">Risk of Bias, Evaluation of Measurement Properties, and Quality of the Evidence</head><p xml:id="_EywRXJY"><s xml:id="_FMbkcbh">Content validity scores are shown in Figure <ref type="figure">2</ref> and Figure <ref type="figure" target="#fig_1">3</ref> and eTable 1 in the Supplement.</s><s xml:id="_QkNvPvY">For psoriasis-specific measures, 4 of the PROM development studies were rated as doubtful (PsoLife, 109 PSORIQoL [UK English], <ref type="bibr" target="#b47">48</ref> PSORIQoL [US English], 49 PQOL12 [US English] 95 ), and the remaining were rated as inadequate.</s><s xml:id="_QFRSqUZ">We identified 3 content validity studies.</s><s xml:id="_2Pm9P3u">The content validity study for the EQ-5D-Pso (Hungarian) <ref type="bibr" target="#b26">27</ref> was of very good quality, whereas the content validity studies for the PDI (Norwegian) <ref type="bibr">101</ref> and PSORIQOL (US English) <ref type="bibr" target="#b48">49</ref> were of doubtful quality.</s><s xml:id="_7Y9tW3q">Overall content validity (combined evidence from development and content validity study) was sufficient for 4 psoriasisspecific PROMs (IPSO-16 [US English], 98 IPSO 10 CTT [US English], 86 IPSO 11 Rasch [US English], 86 and the PQOL41 [US English] 95 ), with very low level of evidence.</s></p><p xml:id="_eD9ufxf"><s xml:id="_ubTKQ5j">For SRQL and generic instruments, all PROM development studies were of doubtful or inadequate quality.</s><s xml:id="_YdWeFev">We identified 4 content  <ref type="bibr" target="#b66">67</ref> ) with very low level of evidence.</s><s xml:id="_Kg5rYpH">No generic PROMs had sufficient content validity.</s><s xml:id="_VDkFPQm">SummariesofmeasurementpropertiesareshownineTables2and 3intheSupplement.</s><s xml:id="_hp4Udpz">No studies evaluated measurement error or measurement invariance.</s><s xml:id="_j5VD9Pp">Most PROMs were considered reflective, but PROMs with symptoms scores or questions about symptomatology (EQ-5D, IPBOD, NAPPAQOL, PsoLife, P-SIM, Psodisk, PQOL12, and PQOL41) were considered mixed because some symptoms-based questions act as causal indicators of HRQL (formative model).</s><s xml:id="_fTcWfpZ">Although we assessed structural validity and internal consistency for these measures, the results may be affected by the mixed structure.</s></p><p xml:id="_yGsXcUh"><s xml:id="_NZDz6Ye">Among psoriasis-specific measures, structural validity was rated sufficient for 9 PROMs (IPSO-10 CTT [US English], 86 IPSO-11 Rasch [US English], 86 IPSO-11 [Italian], 106 NPQ10 [French], <ref type="bibr" target="#b44">45</ref> NAPPAQOL [German, English, Danish, Japanese, Italian, and Spanish], <ref type="bibr" target="#b71">72</ref> PQLQ [Turkish], <ref type="bibr" target="#b42">43</ref> PsoLife [Spanish], 109 PSORIQoL [UK English, US English], <ref type="bibr" target="#b47">48,</ref><ref type="bibr" target="#b48">49</ref> QualiPso [French] 110 ) and quality of evidence was high for IPSO-11 Rasch, IPSO-11, and PSORIQoL and moderate for the remaining 6 PROMs.</s><s xml:id="_Mk9zj3m">Nine measures had insufficient structural validity (IBOP [French], 66 IPSO-16 [US English], 86 PDI [US English, 105 UK English, 103 Chinese, 80 Norwegian, 101 Persian, 65 Sinhala 111 ], PLSI [UK English]).</s><s xml:id="_9T9duK8">GRADE score was high for the IBOP [French and US English], IPSO-16 [US English], and the PDI [US English] and moderate for the remaining 6 PROMs.</s><s xml:id="_vFUmXZ3">Seven psoriasis-specific PROMs (IPSO-11 Rasch [US English], 86 IPSO-11 [Italian], 106 NPQ10 [French], <ref type="bibr" target="#b44">45</ref> NAPPAQOL [German, English, Danish, Japanese, Italian, and Spanish], <ref type="bibr" target="#b71">72</ref> PsoLife [Spanish], 109 PSORIQOL [UK English, <ref type="bibr" target="#b47">48</ref> US English 49 ], and QualiPso [French] 110 ) had sufficient internal consistency with high-quality evidence.</s><s xml:id="_UfysPaZ">Internal consistency was insufficient for 3 measures (IPSO-10 CTT [US English], 86 IPSO-16 [ US English], <ref type="bibr">86</ref> and PQLQ [Turkish] <ref type="bibr" target="#b42">43</ref> ), with all having a high GRADE score except the PQLQ (very low).</s><s xml:id="_jQUQjYj">Responsiveness was assessed for 7 measures. <ref type="bibr" target="#b45">46,</ref><ref type="bibr" target="#b46">47,</ref><ref type="bibr" target="#b63">64,</ref><ref type="bibr">104,</ref><ref type="bibr">109,</ref><ref type="bibr">113,</ref><ref type="bibr">118,</ref><ref type="bibr">120</ref></s><s xml:id="_CBRzt3U">The Psodisk (Italian) <ref type="bibr">120</ref> and PLSI (US English) 104 had insufficient responsiveness with low and moderate GRADE scores, respectively.</s><s xml:id="_uDrK4es">For SRQL measures, 4 PROMs were found to have sufficient structural validity (DLQI [Chinese], 80 DLQI [Italian], 117 DLQI [Norwegian], 99 and Skindex-29 [German] 56 ).</s><s xml:id="_jbBvuCY">Level of evidence was high for the DLQI [Chinese] and moderate for the others.</s><s xml:id="_FH4K6bW">Four measures (DLQI [Chinese], 80 DLQI [Italian], 117 DLQI [Norwegian], 99 Skindex-16 [Ukrainian], 60 and the Skindex-29 [German] 56 had highquality evidence for sufficient internal consistency.</s><s xml:id="_aybJThZ">Five SRQL PROMs (DLQI [US English], 87,107,114 DLQI [Danish], 38 DLQI [German], 37 DLQI [Spanish], <ref type="bibr" target="#b63">64,</ref><ref type="bibr" target="#b69">70</ref> and Scalpdex [Italian]) 84 had sufficient responsiveness with moderate level of evidence, except for Scalpdex, which had a high GRADE score.</s></p><p xml:id="_QdbwgHd"><s xml:id="_YTd59Ew">For generic measures, no studies were identified evaluating structural validity.</s><s xml:id="_EF8dpeE">Internal consistency was assessed for 1 measure (WHOQOL-100) <ref type="bibr" target="#b61">62</ref> and found to be sufficient with a high GRADE score.</s><s xml:id="_3urz3E4">Responsiveness was assessed for 3 measures (SF-36 [US English], 107 EQ-5D-5L [Chinese; Index score], <ref type="bibr" target="#b51">52,</ref><ref type="bibr" target="#b57">58</ref> and the EQ-5D-3L [US English; index score, VAS]), <ref type="bibr">107</ref> which was sufficient with high GRADE scores for all 3.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_MapgJy5">Recommendations of PROMs Use in Psoriasis</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_jMKcY4v">Discussion</head><p xml:id="_vrmphXE"><s xml:id="_ByH2pJ9">We identified 19 psoriasis-specific, 8 skin-specific, and 6 generic PROMs to assess HRQL in patients with psoriasis, along with trans- Inconsistent EQ-5D-Pso (UK English) <ref type="bibr" target="#b46">47,</ref><ref type="bibr">132</ref> Very low Insufficient Very low Sufficient Very low Inconsistent Very low Inconsistent EQ-5D-Pso (Hungarian) <ref type="bibr" target="#b26">27,</ref><ref type="bibr" target="#b46">47,</ref><ref type="bibr">132</ref> Very low Insufficient High Sufficient High Inconsistent Moderate Sufficient I-BOP (French, US English) <ref type="bibr" target="#b65">66</ref> Very low Insufficient Very low Inconsistent Very low Inconsistent Very low Insufficient IPBOD (US English) 92 Very low Sufficient Very low Insufficient Very low Inconsistent Very low Sufficient IPSO-16 (US English) 86 Very low Sufficient Very low Sufficient Very low Sufficient Very low Sufficient IPSO-10 CTT (US English) 86 Very low Sufficient Very low Sufficient Very low Sufficient Very low Sufficient IPSO-11 Rasch (US English) 86 Very low Sufficient Very low Sufficient Very low Sufficient Very low Insufficient NPQ10 (French) 45 Very low Insufficient Very low Sufficient Very low Inconsistent Very low Inconsistent NAPPA-QoL (German, UK English) 72 Very low Sufficient Very low Sufficient Very low Inconsistent Very low Sufficient PDI (UK English) 40 Very low Insufficient Very low Sufficient Very low Inconsistent Very low Sufficient PDI (Norwegian) 40,101 Moderate Insufficient Very low Sufficient Moderate Inconsistent Low Inconsistent PLSI (US English) 104 Very low Insufficient Very low Indeterminate a Very low Inconsistent Very low Inconsistent PQLQ (Turkish) 43 Very low Insufficient Very low Sufficient Very low Inconsistent Very low Inconsistent P-SIM 44 Very low Insufficient Very low Sufficient Very low Inconsistent Very low Sufficient PSOdisk (US English, Italian) 78 Very low Insufficient Very low Sufficient Very low Inconsistent Very low Inconsistent PSO-LIFE (Spanish) 109 Very low Insufficient Very low Sufficient Very low Inconsistent Very low Sufficient PSORIQoL (UK English, Italian, and Dutch) 48 Low Insufficient Very Low Sufficient Very low Inconsistent Very low Sufficient PsoriQOL (US English) 49 Low Insufficient Very Low Sufficient Very low Inconsistent Very low Sufficient PQOL-12 (US English) 95 Very Low Insufficient Very Low Sufficient Very low Inconsistent Very low Sufficient PQOL41 (US English) 95 Very Low Sufficient Very Low Sufficient Very low Sufficient Very low Indeterminate a QLICD-PS (V2.0) (Chinese) 46 Very Low Indeterminate a Very Low Indeterminate a Very low Indeterminate a Very low Indeterminate a QualiPso (French) 110 Very Low Sufficient Very Low Sufficient Very low Indeterminate a Very low Comprehensiveness Comprehensibility Overall EQ-5D-Pso indicates Psoriasis-specific EuroQol five-dimensional questionnaire; I-BOP, Individual Burden of Psoriasis; IPBOD, Inverse Psoriasis Burden of Disease; IPSO-16, Impact of Psoriasis Questionnaire (16 questions); IPSO-10 CTT, Impact of Psoriasis Questionnaire (10 questions, derived using Classic Test Theory); IPSO-11 Rasch Impact of Psoriasis Questionnaire (11 questions, derived using Rasch methods); NPQ10, Nail Psoriasis Quality of Life Scale; NAPPA-QoL, Nail Assessment in Psoriasis and Psoriatic Arthritis Quality of Life; PDI, Psoriasis Disability Index; PLSI, Psoriasis Life Stress Inventory; PQLQ, Psoriasis Quality of Life Questionnaire; P-SIM, Psoriasis Impact and Symptoms Measure; PSORIQoL; PQOL-12, Psoriasis Quality of Life (12 items); PQOL41, Psoriasis Quality of Life (41 items); QLICD-PS (V2.0), Psoriasis-specific Quality of Life Instruments for Chronic Diseases version number 2. a The instrument form of the PROM was not available for reviewers to evaluate the content validity of the instrument.</s></p><p xml:id="_PnJwQWk"><s xml:id="_wUkBhcj">consistency.</s><s xml:id="_RFgRvzW">This gap in knowledge can be attributed to the fact that most measures were developed using validation criteria that differ from the current standards set by COSMIN.</s><s xml:id="_nx2Qmg4">As a result, further validation studies in line with modern standards are needed to assist researchers and clinicians in selecting the most appropriate HRQL measures for psoriasis.</s></p><p xml:id="_smuUYxz"><s xml:id="_rhZtbZy">According to COSMIN standards (sufficient content validity, structural validity, and internal consistency), only 1 measure, the Rasch reduced version of the Impact of Psoriasis Questionnaire (IPSO-11 Rasch), 86 received an A recommendation for use.</s><s xml:id="_zemdyjm">However, it is important to note that data were not available for reliability, construct validity, or responsiveness for this version (though there are data to support the construct validity of its parent measure, the IPSO-16).</s><s xml:id="_xdxxGEn">In addition, the evidence for content validity was of very low quality (ie, only based on reviewer ratings).</s><s xml:id="_wQvUjZV">Therefore, al-though the IPSO-11 Rasch met the COSMIN criteria to receive an A recommendation, there is a need for additional studies to confirm its content validity and other measurement properties.</s><s xml:id="_vwpYVWQ">The PSORIQoL, NPQ10, and the NAPPAQOL had sufficient structural validity and internal consistency, but evidence supporting their content validity was limited.</s><s xml:id="_3TtRCP9">If further data were available to confirm the content validity of these measures, they could receive an A recommendation for use.</s></p><p xml:id="_kYk2pZ4"><s xml:id="_fvZXXXk">Among dermatology-specific measures, both the Skindex-16 <ref type="bibr" target="#b66">67</ref> and the DLQI <ref type="bibr" target="#b40">41</ref> have received recommendations for use, indicating their potential but requiring further validation.</s><s xml:id="_tavyw7j">The US English version of Skindex-16 demonstrated sufficient content validity (very low quality), although data on its structural validity and internal consistency were not available.</s><s xml:id="_AzAa3Cq">The DLQI had inconsistent evidence for content validity.</s><s xml:id="_5aXpay2">Whereas Safikhani et al 82 concluded that the DLQI Overall content validity Relevance Rating Instrument Dermatology Specific Generic Grade Rating Grade Rating Grade Rating Grade Inconsistent DLQI (UK English) 41,50 Very low Insufficient High Sufficient High Inconsistent Moderate Inconsistent EDLQI (US English) 41,82 Low Insufficient Very low Sufficient Moderate Inconsistent Very low Sufficient DQOLS (UK English) 42 Very low Insufficient Very low Sufficient Very low Sufficient Very low Inconsistent FLQA (German) 108 Very low Insufficient Very low Sufficient Very low Inconsistent Very low Insufficient ISDL (Dutch) 97 Very low Sufficient Very low Indeterminate a Very low Inconsistent Very low Sufficient Scalpex (US English) 91 Very low Insufficient Very low Sufficient Very low Inconsistent Very low Sufficient Skindex-16 (US English) 67,93 Low Sufficient Very low Sufficient Very low Sufficient Very low Sufficient Skindex-17 (US English) 93,94 Low Insufficient Very low Sufficient Very low Inconsistent Very low Sufficient Skindex-29 (UK English) 50,93 Low Inconsistent Moderate Sufficient High Inconsistent Moderate Sufficient Skindex-29 (US English) 93 Low Insufficient Very low Sufficient Very low Inconsistent Very low Sufficient EuroQol (Dutch, UK English, Finnish, Norwegian, Swedish) 132 Very low Insufficient Very low Sufficient Very low Inconsistent Very low PRISM (UK English) 57 Inconsistent QOLS (US English) 29,85 Very low Insufficient Very low Sufficient Very low Inconsistent Very low (1) (1) (1) (1) (1) (1) (1) (1) Inconsistent SF-36 (US English) 133 Very low Insufficient Very low Sufficient Very low Inconsistent Very low Inconsistent WHOQOL-100 (Multicentric) 96 Very low Insufficient Very low Sufficient Very low Inconsistent Very low Comprehensiveness Comprehensibility Overall Cells marked as (1) indicate that these were unratable due to the design of the PROM.</s><s xml:id="_xPv5QGj">DLQI indicates Dermatology Life Quality Index; DQOLS, Dermatology quality of life scales; EQ5D-5d-5L, EQ5D-5d-3L, EuroQol 5-dimensional questionnaire (3 levels of response); EQ VAS, EuroQol 5-dimensional questionnaire (5 levels of response); EuroQol visual analogue scale; FLQA, Freiburg Life Quality Assessment; ISDL, Impact of Chronic Skin Disease on Daily Life; PRISM, Pictorial representation of Illness and self-measure; QOLS-N, Quality of Life Scale; SF-36, 36-Item Short Form Survey; SRQL, Skin-related Quality of Life; WHOQOL-100, World Health Organization Quality of Life. a The instrument form of the PROM was not available for reviewers to evaluate the content validity of the instrument.</s></p><p xml:id="_kNgbzrD"><s xml:id="_besPzdw">included all relevant concepts, Paudyal et al <ref type="bibr" target="#b49">50</ref> reported that the DLQI may not adequately capture the emotional effects experienced by individuals with psoriasis.</s><s xml:id="_qJF7f9y">However, it is important to acknowledge that the assessment of comprehensiveness is challenging because items that are strongly correlated may be deleted during measure development to improve feasibility.</s><s xml:id="_mdxsffz">In addition, the high prevalence of not relevant responses on the DLQI raised concerns about its content validity and potential for bias when used among diverse populations. <ref type="bibr" target="#b50">51,</ref><ref type="bibr">116,</ref><ref type="bibr">122</ref></s><s xml:id="_nNur32W">Results regarding the structural validity of the DLQI varied across different language versions, with the UK English version showing insufficient structural validity.</s><s xml:id="_vbFMNkJ">In contrast, studies showed that the DLQI [Spanish, <ref type="bibr" target="#b63">64,</ref><ref type="bibr" target="#b69">70</ref> English US, 87,107,114 German, <ref type="bibr" target="#b36">37</ref> and Danish 38 ] was able to capture change in SRQL over time.</s><s xml:id="_gP9EDMZ">Overall, these findings underscore the importance of additional validation studies for the various versions of the DLQI.</s><s xml:id="_Hhc3DVB">There was a lack of studies examining the content validity, structural validity, and internal consistency of generic HRQL measures such as the EQ-5D and SF-36 in the context of psoriasis.</s><s xml:id="_Rtrqb6j">However, it is worth noting that the English versions of the EQ-5D-3L and SF-36 demonstrated high-quality evidence for sufficient responsiveness, 107 indicating their ability to detect changes HRQL over time in this population.</s><s xml:id="_SzXFEn2">In particular, the SF-36 has shown promise in detecting clinically meaningful treatment-associated improvements in psoriasis and has demonstrated low evidence of ceiling effects, which means it can capture improvements even when patients are already functioning at a highlevel. 123</s><s xml:id="_e5xZECg">OMERACT(OutcomeMeasuresinRheumatology)hasrecognized the value of using generic HRQL measures alongside diseasespecific measures because they capture different aspects of the effects of the disease. <ref type="bibr">[124]</ref><ref type="bibr">[125]</ref></s><s xml:id="_XPPxGp7">5]<ref type="bibr">[126]</ref><ref type="bibr">[127]</ref> Overall, these findings highlight the need for studies exploring the content validity, structural validity, and internal consistency of generic HRQL measures in the context of psoriasis to enhance their utility in clinical practice and research.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_5zgY4sc">Limitations</head><p xml:id="_SmpvEDz"><s xml:id="_QWNMQnb">It is possible that some studies were performed according to the standards outlined by COSMIN, but that these details were not included in the resulting publications.</s><s xml:id="_mmfJKb3">This issue may be particularly common among studies published prior to the COSMIN initiative start in 2005.</s><s xml:id="_SvAfNSK">Because only aspects of studies that were reported can be assessed, it is possible that we may underestimate the quality of the evidence for some of the examined PROMs.</s><s xml:id="_rZHPZbJ">Another limitation is that several aspects of the COSMIN risk of bias checklist are somewhat subjective.</s><s xml:id="_J29HGxA">To mitigate potential reviewer bias, we discussed and formalized assumptions for these situations a priori and created rubrics to improve consistency (see methodology for assessing comprehensiveness of PROMs, Supplement).</s><s xml:id="_y4pvRvz">Although the COSMIN framework has certain limitations, it offers a formal framework from which to assess the quality of PROM development and measurement properties. <ref type="bibr">[128]</ref><ref type="bibr">[129]</ref></s><s xml:id="_cwck3XQ">]<ref type="bibr">[130]</ref> Although COSMIN primarily recommends that only 1 literature search is conducted using the following strategy: (1) construct, (2) population(s), (3) type of instrument(s), and (4) measurement properties, we used an alternative 2-stage strategy also described in the COSMIN manual by which we first identified all PROMs that have been used in patients with psoriasis (stage 1) and subsequently searched for validation studies for all PROMs identified in stage 1 (stage 2).</s><s xml:id="_yU7GvaZ">Although we suspect that this strategy would yield similar results to the recommended approach described in the COS-MIN manual, it is possible that important development, pilot, or validation studies were missed.</s><s xml:id="_EwKjyCg">In addition, because PROM development and validation work is an ongoing process, future updates to this review will be important to guide decisions on PROM use.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_6YYhqh4">Conclusions</head><p xml:id="_bnqJh5v"><s xml:id="_5kD3C4E">Most of the identified measures received a B recommendation for use, indicating their potential to be recommended but requiring further validation.</s><s xml:id="_rmwfNbu">Only the Rasch reduced IPSO-11 was found to be sufficiently valid with respect to the COSMIN standards.</s><s xml:id="_WtGtGPt">Therefore, additional research that follows modern psychometric standards would be highly beneficial for researchers and clinicians in their endeavor to choose the most suitable HRQL measure for patients with psoriasis.</s></p><p xml:id="_HB3WvG7"><s xml:id="_xVrShNK">76. Rencz F, Gulácsi L, Péntek M, et al.</s><s xml:id="_4BaKkkQ">Proposal of a new scoring formula for the Dermatology Life Quality Index in psoriasis.</s><s xml:id="_XUPnqqa">Br J Dermatol.</s><s xml:id="_4xK7HR3">2018;179 (5):1102-1108.</s><s xml:id="_3wPKxEb">doi:10.1111/bjd.16927</s><s xml:id="_8tTY9sm">77.</s><s xml:id="_Av42pa9">Cozzani E, Linder D, Burlando M, et al.</s><s xml:id="_XYw79Nt">PSOdisk is a reliable, intuitive instrument for the evaluation of psychological distress, which strongly correlates with DLQI: a preliminary study.</s><s xml:id="_XfgzenA">Eur J Dermatol.</s><s xml:id="_UFeWdyK">2018;28(3):332-337.</s><s xml:id="_hBhXhvv">doi:10.1684/ejd.2018.3301</s><s xml:id="_n9SPwYm">78.</s><s xml:id="_UtHrmCM">Linder D, Sampogna F, Torreggiani A, et al.</s><s xml:id="_vrJP8Tr">Psodisk, a new visual method for assessing the burden of psoriasis on patients.</s><s xml:id="_ynrSgeU">J Eur Acad Dermatol Venereol.</s><s xml:id="_ET3UnpY">2012;26(9):1163-1166. doi:10.</s><s xml:id="_9U5YnXc">1111/j.1468-3083.2011.04192.x</s><s xml:id="_bhsZ4SK">79.</s><s xml:id="_ssHPPyF">Meneguin S, de Souza Matos TD, Pollo CF, Garuzi M, Miot HA, de Oliveira C. Psychometric characteristics of DLQI-BRA and Skindex-16 to measure the impact of dermatological diseases on quality of life in Brazilian patients.</s><s xml:id="_SdrGwTM">PLoS One.</s><s xml:id="_bH5Ykac">2021;16(8):e0254882. doi:10.1371/journal.pone.</s><s xml:id="_x97D5ty">0254882 80.</s><s xml:id="_CnnUuCw">He Z, Lu C, Basra MK, Ou A, Yan Y, Li L. Psychometric properties of the Chinese version of Dermatology Life Quality Index (DLQI) in 851 Chinese patients with psoriasis.</s><s xml:id="_QVmgKhh">J Eur Acad Dermatol Venereol.</s><s xml:id="_2FDtrDA">2013;27(1):109-115.</s><s xml:id="_QusrJjs">doi:10.1111/j.</s><s xml:id="_wnF38g7">1468-3083.2011.04371.x</s><s xml:id="_pE9mMYH">81.</s><s xml:id="_26ftsdq">Mazzotti E, Picardi A, Sampogna F, Sera F, Pasquini P, Abeni D; IDI Multipurpose Psoriasis Research on Vital Experiences study group.</s><s xml:id="_bpfCZQK">Sensitivity of the Dermatology Life Quality Index to clinical change in patients with psoriasis.</s><s xml:id="_4Ds4nba">Br J Dermatol.</s><s xml:id="_8NFWkwX">2003;149(2):318-322. doi:10.1046/j.1365-2133.2003.05378.x</s><s xml:id="_zMFNcFe">82.</s><s xml:id="_CAVXSyD">Safikhani S, Sundaram M, Bao Y, Mulani P, Revicki DA.</s><s xml:id="_vXW7mph">Qualitative of the validity of the Dermatology Life Quality Index in patients with moderate to severe psoriasis.</s><s xml:id="_Sr9xJ3W">J Dermatolog Treat.</s><s xml:id="_QpzqunX">2013;24(1):50-59.</s><s xml:id="_PWEVT2n">doi:10.3109/</s><s xml:id="_UnV9Er5">09546634.2011.631980</s><s xml:id="_uemrpAY">83.</s><s xml:id="_af5Mbhn">Touw CR, Hakkaart-Van Roijen L, Verboom P, Paul C, Rutten FF, Finlay AY.</s><s xml:id="_kUy8NvY">Quality of life and clinical outcome in psoriasis patients using intermittent cyclosporin.</s><s xml:id="_7D98GCe">Br J Dermatol.</s><s xml:id="_H4Qgc9C">2001;144 (5):967-972.</s><s xml:id="_Va4e5yM">doi:10.1046/j.1365-2133.2001.04183.x</s><s xml:id="_evZT5CP">84.</s><s xml:id="_R6Z6K5d">Sampogna F, Linder D, Piaserico S, et al.</s><s xml:id="_qrmPfwz">Quality of life assessment of patients with scalp dermatitis using the Italian version of the Scalpdex.</s><s xml:id="_pgdC37A">Acta Derm Venereol.</s><s xml:id="_GqTznwG">2014;94(4):411-414.</s><s xml:id="_EC75RwK">doi:10.2340/</s><s xml:id="_E2yXC7j">00015555-1731 85.</s><s xml:id="_MA5hUhD">Burckhardt CS, Woods SL, Schultz AA, Ziebarth DM.</s><s xml:id="_v3bQCKb">Quality of life of adults with chronic illness: a psychometric study.</s><s xml:id="_XJsUpHc">Res Nurs Health.</s><s xml:id="_3dyYrpr">1989;12(6): 347-354.</s><s xml:id="_4rDGTrM">doi:10.1002/nur.4770120604</s><s xml:id="_Qd7B4zh">86.</s><s xml:id="_RqzuUNE">Nijsten T, Unaeze J, Stern RS.</s><s xml:id="_cv8zAks">Refinement and reduction of the Impact of Psoriasis Questionnaire: classical test theory vs. Rasch analysis.</s><s xml:id="_jTK65Pk">Br J Dermatol.</s><s xml:id="_B2fqap2">2006;154(4):692-700. doi:10.1111/j.1365-2133.2005.</s><s xml:id="_y7M5har">07066.x</s><s xml:id="_NBZX8cE">87.</s><s xml:id="_T3RJSNf">Revicki DA, Willian MK, Menter A, Saurat JH, Harnam N, Kaul M. Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis.</s><s xml:id="_zYxcPqg">Dermatology.</s><s xml:id="_b8qv34v">2008;216(3):260-270. doi:10.1159/000113150</s><s xml:id="_djvtqkn">88.</s><s xml:id="_uBrNzUd">He Z, Lu C, Ou A, et al.</s><s xml:id="_3rfcdEk">Reliability and validity of the Chinese version of the Psoriasis Disability Index (PDI) in Chinese patients with psoriasis.</s><s xml:id="_6EJCv96">Health Qual Life Outcomes.</s><s xml:id="_gnBJVyr">2012;10:37.</s><s xml:id="_Y5frCwe">doi:10.1186/1477-7525-10-37</s><s xml:id="_EHDYG53">89.</s><s xml:id="_jRdyU7N">Sampogna F, Linder D, Romano GV, Gualberti G, Merolla R, di Luzio Paparatti U. Results of the validation study of the Psodisk instrument, and determination of the cut-off scores for varying degrees of impairment.</s><s xml:id="_8BFPZjG">J Eur Acad Dermatol Venereol.</s><s xml:id="_xMgeHhM">2015;29(4):725-731.</s><s xml:id="_py7zwCz">doi:10.1111/jdv.12668</s><s xml:id="_P5wmZeH">90.</s><s xml:id="_gcF7vCV">Vakil-Gilani KM, Dinno A, Rich-Garg N, Deodhar A. Routine Assessment of Patient Index Data 3 Score and Psoriasis Quality of Life assess complementary yet different aspects of patient-reported outcomes in psoriasis and psoriatic arthritis.</s><s xml:id="_2HJNq2h">J Clin Rheumatol.</s><s xml:id="_VYUh2G7">2018;24(6): 319-323.</s><s xml:id="_YDjeHxt">doi:10.1097/RHU.0000000000000630</s><s xml:id="_TyrvZKN">91.</s><s xml:id="_v6RWXpx">Chen SC, Yeung J, Chren MM.</s><s xml:id="_htehE2n">Scalpdex: a quality-of-life instrument for scalp dermatitis.</s><s xml:id="_GwBy5HC">Arch Dermatol.</s><s xml:id="_S66p4FD">2002;138(6):803-807. doi:10.1001/</s><s xml:id="_GcqzM5r">archderm.138.6.803</s><s xml:id="_d5kHwck">92.</s><s xml:id="_BArDF2U">Cohen JM, Halim K, Joyce CJ, Patel M, Qureshi AA, Merola JF.</s><s xml:id="_JYK5fa9">Shedding light on the "hidden psoriasis": a pilot study of the Inverse Psoriasis Burden of Disease (IPBOD) Questionnaire.</s><s xml:id="_GGdybzE">J Drugs Dermatol.</s><s xml:id="_7RbKbcT">2016;15(8):1011-1016. 93.</s><s xml:id="_h5Nbsz4">Chren MM, Lasek RJ, Quinn LM, Mostow EN, Zyzanski SJ.</s><s xml:id="_b4grJMn">Skindex, a quality-of-life measure for patients with skin disease: reliability, validity, and responsiveness.</s><s xml:id="_dV4QAdR">J Invest Dermatol.</s><s xml:id="_EPfq6SA">1996;107(5): 707-713.</s><s xml:id="_vfvFM65">doi:10.1111/1523-1747.ep12365600</s><s xml:id="_9KyxzrY">94.</s><s xml:id="_Bq76Qgf">Nijsten TE, Sampogna F, Chren MM, Abeni DD.</s><s xml:id="_fbNquFE">Testing and reducing skindex-29 using Rasch analysis: Skindex-17.</s><s xml:id="_fcJsuKf">J Invest Dermatol.</s><s xml:id="_VkPwX9y">2006;126 (6):1244-1250.</s><s xml:id="_tgS3ZzY">doi:10.1038/sj.jid.5700212</s><s xml:id="_etAh2Uw">95.</s><s xml:id="_B6Cw2KE">Koo J, Kozma CM, Reinke K.</s><s xml:id="_ctqXxpA">The Development of a Disease-Specific Questionnaire to Assess Quality of Life for Psoriasis Patients: An Analysis of the Reliability, Validity, and Responsiveness of the Psoriasis Quality of Life Questionnaire.</s><s xml:id="_QQXZtYR">Dermatologie und Psychosomatik.</s><s xml:id="_jN5uaSd">2003;3(4):171-179.</s><s xml:id="_fEhMGGk">doi:10.1159/000069253</s><s xml:id="_KEyvxWV">96.</s><s xml:id="_F2EWQfn">The Development of the World Health Organization Quality of Life Assessment Instrument.</s><s xml:id="_8dYEGfh">(the WHOQOL).</s><s xml:id="_vhSPnae">Springer Berlin Heidelberg; 1994:41-57.</s><s xml:id="_mngrCeP">97.</s><s xml:id="_cNuWKrr">Evers AW, Duller P, van de Kerkhof PC, et al.</s><s xml:id="_NXXBh7q">The Impact of Chronic Skin Disease on Daily Life (ISDL): a generic and dermatology-specific health instrument.</s><s xml:id="_pgNr2dV">Br J Dermatol.</s><s xml:id="_NG5b22a">2008;158(1):101-108. 98. McKenna KE, Stern RS.</s><s xml:id="_Tmf53NZ">The impact of psoriasis on the quality of life of patients from the 16-center PUVA follow-up cohort.</s><s xml:id="_GyeTQvG">J Am Acad Dermatol.</s><s xml:id="_ada254j">1997; 36(3 Pt 1):388-394.</s><s xml:id="_7w5cE2r">doi:10.1016/S0190-9622(97)</s><s xml:id="_eNZmjT7">80214-9 99.</s><s xml:id="_HphCjry">Mørk C, Wahl A, Moum T. The Norwegian version of the dermatology life quality index: a study of validity and reliability in psoriatics.</s><s xml:id="_s9rrPvm">Acta Derm Venereol.</s><s xml:id="_kZrtkzw">2002;82(5):347-351.</s><s xml:id="_UDJUgSw">doi:10.1080/</s><s xml:id="_qaZc2xs">000155502320624078 100.</s><s xml:id="_32JaQCg">Wahl A, Burckhardt C, Wiklund I, Hanestad BR.</s><s xml:id="_bkrTRjT">The Norwegian version of the Quality of Life Scale (QOLS-N).</s><s xml:id="_TTRF44X">A validation and reliability study in patients suffering from psoriasis.</s><s xml:id="_SQgrZQb">Scand J Caring Sci.</s><s xml:id="_x5a5VcA">1998;12(4):215-222.</s><s xml:id="_Pm3TQdc">doi:10.1080/</s><s xml:id="_KqWdy6h">02839319850162823 101.</s><s xml:id="_hxcNuv4">Wahl AK, Wiklund I, Moum T, Hanestad BR.</s><s xml:id="_Kw3EEag">The Norwegian version of the psoriasis disability index-a validation and reliability study.</s><s xml:id="_AZ2VDSN">Value Health.</s><s xml:id="_PeKF5vw">1999;2(5):342-349.</s><s xml:id="_auVpWBj">doi:10.1046/j.1524-4733.1999.</s><s xml:id="_FTcSv2k">25002.x</s><s xml:id="_GVsRzNq">102.</s><s xml:id="_vsCXeZs">Janowski K, Steuden S, Bereza B. The Polish version of Skindex-29: psychometric properties of an instrument to measure quality of life in dermatology.</s><s xml:id="_tJ3vJFG">Postepy Dermatol Alergol.</s><s xml:id="_PuhwUan">2014;31(1): 12-20.</s><s xml:id="_p7vNbBU">doi:10.5114/pdia.2014.40654</s><s xml:id="_wGR89Vr">103.</s><s xml:id="_XXxedjv">Kent G, al-Abadie M. The Psoriasis Disability Index-further analyses.</s><s xml:id="_zeCHbaE">Clin Exp Dermatol.</s><s xml:id="_qVmMnRY">1993;18 (5):414-416.</s><s xml:id="_ju4GuU4">doi:10.1111/j.1365-2230.1993.tb02239.x</s><s xml:id="_XYZdpVq">104.</s><s xml:id="_7R3WPEF">Gupta MA, Gupta AK.</s><s xml:id="_bPv4twc">The Psoriasis Life Stress Inventory: a preliminary index of psoriasis-related stress.</s><s xml:id="_GBs7CuT">Acta Derm Venereol.</s><s xml:id="_YeQMV8Y">1995;75(3):240-243.</s><s xml:id="_WY9PsCG">doi:10.2340/0001555575240243</s><s xml:id="_UFrUpSa">105.</s><s xml:id="_nRxcmGX">Nijsten T, Whalley D, Gelfand J, Margolis D, McKenna SP, Stern RS.</s><s xml:id="_gNH433Q">The psychometric properties of the psoriasis disability index in United States patients.</s><s xml:id="_vzT5Bpj">J Invest Dermatol.</s><s xml:id="_6htFS9n">2005;125(4):665-672. doi:10.1111/j.0022-202X.2005.23775.x</s><s xml:id="_yJH29ER">106.</s><s xml:id="_8zhN5mA">Nijsten T, Sampogna F, Stern RS, Abeni D. The reduced Impact of Psoriasis Questionnaire has good psychometric properties in Italian patients.</s><s xml:id="_EVbgmnQ">Dermatology.</s><s xml:id="_cytvyNE">2007;215(4):348-351. doi:10.1159/</s><s xml:id="_jnGEzrr">000107629 107.</s><s xml:id="_tJRFGmD">Shikiar R, Willian MK, Okun MM, Thompson CS, Revicki DA.</s><s xml:id="_N6HuaHw">The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study.</s><s xml:id="_5EkaGSh">Health Qual Life Outcomes.</s><s xml:id="_73xVCWp">2006;4:71.</s><s xml:id="_XVpkdng">doi:10.1186/1477-7525-4-71</s><s xml:id="_EkXAa9m">108.</s><s xml:id="_uaufkK5">Augustin M, Lange S, Wenninger K, Seidenglanz K, Amon U, Zschocke I. Validation of a comprehensive Freiburg Life Quality Assessment (FLQA) core questionnaire and development of a threshold system.</s><s xml:id="_MJT6QGy">Eur J Dermatol.</s><s xml:id="_bAFCDvT">2004;14(2):107-113.</s><s xml:id="_W57gdDd">109.</s><s xml:id="_KrjMCuh">Dauden E, Herrera E, Puig L, et al.</s><s xml:id="_Yx5SjFU">Validation of a new tool to assess health-related quality of life in psoriasis: the PSO-LIFE questionnaire.</s><s xml:id="_QxAmJse">Health Qual Life Outcomes.</s><s xml:id="_nvRp4gy">2012;10(1):56.</s><s xml:id="_7EuXYmv">doi:10.1186/</s><s xml:id="_Be3FvPX">1477-7525-10-56 110.</s><s xml:id="_TRH8kRt">Quintard B, Constant A, Bouyssou-Gauthier ML, et al.</s><s xml:id="_TGMPj2r">Validation of a specific health-related quality of life instrument in a large cohort of patients with psoriasis: the QualiPso Questionnaire.</s><s xml:id="_MtuQUuT">Acta Derm Venereol.</s><s xml:id="_FuRNjTq">2011;91(6):660-665.</s><s xml:id="_GHkB2bm">doi:10.</s><s xml:id="_VP6VYbR">2340/00015555-1137 111.</s><s xml:id="_CmW3Qjv">Liyanage A, Liyanage G, De Silva V, et al.</s><s xml:id="_4vrjQ3A">Validation of psoriasis disability index (PDI) questionnaire Sinhala version.</s><s xml:id="_QFcgAuU">Arch Dermatol Res.</s><s xml:id="_xhtWdch">2022;314(1):61-69.</s><s xml:id="_6pBrytB">doi:10.1007/s00403-021-02210-5</s><s xml:id="_eAM5kh2">112.</s><s xml:id="_xxsuwku">Finlay AY, Khan GK, Luscombe DK, Salek MS.</s><s xml:id="_vakqYgq">Validation of Sickness Impact Profile and Psoriasis Disability Index in Psoriasis.</s><s xml:id="_gW4W6C8">Br J Dermatol.</s><s xml:id="_TNyh5Xe">1990;123 (6):751-756.</s><s xml:id="_53jT75U">doi:10.1111/j.1365-2133.1990.tb04192.x</s><s xml:id="_4CQmX7v">113.</s><s xml:id="_7he69VQ">Vanaclocha F, Puig L, Daudén E, et al. [Validation of the Spanish version of the Psoriasis Disability Index questionnaire in assessing the quality of life of patients with moderate-severe psoriasis].</s><s xml:id="_UQCMvUF">Actas Dermosifiliogr.</s><s xml:id="_XTgvD4Z">2005;96(10):659-668. doi:10.1016/S0001-7310(05)73154-9</s><s xml:id="_StAfUwy">114.</s><s xml:id="_QwA3NYx">Shikiar R, Bresnahan BW, Stone SP, Thompson C, Koo J, Revicki DA.</s><s xml:id="_uuaBW4q">Validity and reliability of patient reported outcomes used in psoriasis: results from two randomized clinical trials.</s><s xml:id="_P96Xz3x">Health Qual Life Outcomes.</s><s xml:id="_Mej5Tgt">2003;1:53.</s><s xml:id="_aZseAFa">doi:10.1186/1477-7525-1-53</s><s xml:id="_MSjdcU7">115.</s><s xml:id="_7CJMjAV">Schiffner R, Brunnberg S, Hohenleutner U, Stolz W, Landthaler M. Willingness to pay and time trade-off: useful utility indicators for the assessment of quality of life and patient satisfaction Patient-Reported Outcome Measures for Health-Related Quality of Life in Patients With Psoriasis Review Clinical Review &amp; Education jamadermatology.com</s><s xml:id="_ECHckHM">(Reprinted) JAMA Dermatology Published online January 24, 2024 E13 © 2024 American Medical Association.</s><s xml:id="_ZrBUcXU">All rights reserved.</s><s xml:id="_4UeW6B8">Downloaded from jamanetwork.com</s><s xml:id="_u4tFu3t">by Leiden University Libraries user on 04/30/2024 in patients with port wine stains.</s><s xml:id="_YXpGNdp">Br J Dermatol.</s><s xml:id="_svY5P24">2002;146(3):440-447. doi:10.1046/j.1365-2133.2002.</s><s xml:id="_cpJUT2m">04613.x</s><s xml:id="_G8Dqx9D">116.</s><s xml:id="_HkxcYs4">Barbieri JS, Shin DB, Syed MN, Takeshita J, Gelfand JM.</s><s xml:id="_bBAsQmd">Evaluation of the Frequency of "Not Relevant" Responses on the Dermatology Life Quality Index by Sociodemographic Characteristics of Patients With Psoriasis.</s><s xml:id="_5GTfpks">JAMA Dermatol.</s><s xml:id="_db7WHCh">2020; 156(4):446-450.</s><s xml:id="_Gsr6NkT">doi:10.1001/jamadermatol.2019.</s><s xml:id="_h2vnHZc">4659 117.</s><s xml:id="_DhP65Tr">Mazzotti E, Barbaranelli C, Picardi A, Abeni D, Pasquini P. Psychometric properties of the Dermatology Life Quality Index (DLQI) in 900 Italian patients with psoriasis.</s><s xml:id="_5ewqcNT">Acta Derm Venereol.</s><s xml:id="_bqU62yt">2005;85(5):409-413.</s><s xml:id="_z2FzDAK">doi:10.1080/</s><s xml:id="_MCyQNty">00015550510032832 118.</s><s xml:id="_WmgcWze">Warren RB, Gottlieb AB, Merola JF, et al.</s><s xml:id="_nzAwe8b">Psychometric validation of the Psoriasis Symptoms and Impacts Measure (P-SIM), a novel patient-reported outcome instrument for patients with plaque psoriasis, using data from the BE VIVID and BE READY Phase 3 Trials.</s><s xml:id="_kBRRJVB">Dermatol Ther (Heidelb).</s><s xml:id="_ejmfNUE">2021;11(5):1551-1569. doi:10.1007/s13555-021-00570-4</s><s xml:id="_WxZMcgd">119.</s><s xml:id="_CA4P4yG">O'Neill P, Kelly P. Postal questionnaire study of disability in the community associated with psoriasis.</s><s xml:id="_uzXQHBT">BMJ.</s><s xml:id="_uxtyTcM">1996;313(7062):919-921. doi:10.</s><s xml:id="_8U4ypJa">1136/bmj.313.7062.919</s><s xml:id="_YDYPpQ8">120.</s><s xml:id="_2Ha6dfY">Chiricozzi A, Bianchi L, Zangrilli A, et al.</s><s xml:id="_QPvSR87">Quality of life of psoriatic patients evaluated by a new psychometric assessment tool: PsoDisk.</s><s xml:id="_HMN3QVQ">Eur J Dermatol.</s><s xml:id="_BPMdXAb">2015;25(1):64-69.</s><s xml:id="_RUrccXC">doi:10.1684/ejd.2014.</s><s xml:id="_HC7Ear2">2473 121.</s><s xml:id="_y4eHusu">Fotiou K, Hofmann M, Kaufmann R, Thaci D. Pictorial representation of illness and self measure (PRISM): an effective tool to assess the burden of psoriasis.</s><s xml:id="_zwGdfhK">J Eur Acad Dermatol Venereol.</s><s xml:id="_fW2MBKy">2015;29 (12):2356-2362.</s><s xml:id="_e9h5ypK">doi:10.1111/jdv.13232</s><s xml:id="_bZEVRHT">122.</s><s xml:id="_gvCd7ej">Barbieri JS, Gelfand JM.</s><s xml:id="_vtjfUks">Influence of "not relevant" responses on the Dermatology Life Quality Index (DLQI) for Patients With Psoriasis in the United States.</s><s xml:id="_VQy6kGD">JAMA Dermatol.</s><s xml:id="_yWaTNUY">2019;155(6): 743-745.</s><s xml:id="_u3NUZ4x">doi:10.1001/jamadermatol.2018.5655</s><s xml:id="_95xNmUz">123.</s><s xml:id="_5m8dm69">Strand V, Sharp V, Koenig AS, et al.</s><s xml:id="_PhuhYyp">Comparison of health-related quality of life in rheumatoid arthritis, psoriatic arthritis and psoriasis and effects of etanercept treatment.</s><s xml:id="_8VAHx6E">Ann Rheum Dis.</s><s xml:id="_e4Y7drd">2012;71(7):1143-1150. doi:10.1136/annrheumdis-2011-200387</s><s xml:id="_pPA9EsS">124.</s><s xml:id="_JmkpKEF">Merkel PA, Herlyn K, Mahr AD, et al.</s><s xml:id="_T6DUt4Q">Progress towards a core set of outcome measures in small-vessel vasculitis.</s><s xml:id="_DJbcEv9">Report from OMERACT 9. J Rheumatol.</s><s xml:id="_YaqUQYP">2009;36(10):2362-2368.</s><s xml:id="_yw3jP9c">doi:10.3899/</s><s xml:id="_apuG2ss">jrheum.090373</s><s xml:id="_awmcwun">125.</s><s xml:id="_daf6FFe">Robson JC, Tomasson G, Milman N, et al.</s><s xml:id="_d7a8NsT">OMERACT endorsement of patient-reported outcome instruments in antineutrophil cytoplasmic antibody-associated vasculitis.</s><s xml:id="_rpvtWRu">J Rheumatol.</s><s xml:id="_rV6CHME">2017; 44(10):1529-1535.</s><s xml:id="_42GpzWU">doi:10.3899/jrheum.161139</s><s xml:id="_9QtpXcC">126.</s><s xml:id="_29jmc9V">Patrick DL, Deyo RA.</s><s xml:id="_kfTHhGp">Generic and disease-specific measures in assessing health status and quality of life.</s><s xml:id="_W6gGDFX">Med Care.</s><s xml:id="_rJqYkZ3">1989;27(3)(suppl): S217-S232.</s><s xml:id="_NZwmZum">doi:10.1097/00005650-198903001-00018</s><s xml:id="_AD5qfjp">127.</s><s xml:id="_sus3jY9">Strand V, Boers M, Idzerda L, et al.</s><s xml:id="_fawZJQg">It's good to feel better but it's better to feel good and even better to feel good as soon as possible for as long as possible.</s><s xml:id="_tJZ33yC">Response criteria and the importance of change at OMERACT 10.</s><s xml:id="_K7PSUjr">J Rheumatol.</s><s xml:id="_4u34sMD">2011;38(8): 1720-1727.</s><s xml:id="_hZ5p65q">doi:10.3899/jrheum.110392</s><s xml:id="_VqeUHac">128.</s><s xml:id="_ntmU5Wa">McKenna SP, Heaney A. COSMIN reviews: the need to consider measurement theory, modern measurement and a prospective rather than retrospective approach to evaluating patient-based measures.</s><s xml:id="_d96yRRD">J Med Econ.</s><s xml:id="_XjX6T3U">2021;24(1):860-861.</s><s xml:id="_QG3TUwJ">doi:10.</s><s xml:id="_24jsPu7">1080/13696998.2021.1948232</s><s xml:id="_8BB5suY">129.</s><s xml:id="_wAFqjdn">McKenna SP, Heaney A. Setting and maintaining standards for patient-reported outcome measures: can we rely on the COSMIN checklists?</s><s xml:id="_DCMYZVf">J Med Econ.</s><s xml:id="_HYJMESm">2021;24(1):502-511.</s><s xml:id="_2tGsK4U">doi:10.</s><s xml:id="_6FkuRv6">1080/13696998.2021.1907092</s><s xml:id="_dPCeEKV">130. Mokkink LB, Terwee CB, Bouter LM, Alonso JA, Patrick D, de Vet HCW.</s><s xml:id="_qCgBtd6">Reply to the concerns raised by McKenna and Heaney about COSMIN.</s><s xml:id="_DFBUeCQ">J Med Econ.</s><s xml:id="_W9nHNyM">2021;24(1):857-859.</s><s xml:id="_asK6kg2">doi:10.1080/</s><s xml:id="_RktSBGb">13696998.2021.1948231</s><s xml:id="_6eWxdbE">131.</s><s xml:id="_yKydpmH">Devlin NJ, Brooks R. EQ-5D and the EuroQol Group: past, present and future.</s><s xml:id="_prDGBEY">Appl Health Econ Health Policy.</s><s xml:id="_bXnn7yN">2017;15(2):127-137.</s><s xml:id="_fjXF3eq">doi:10.1007/</s><s xml:id="_v5shZtX">s40258-017-0310-5 132.</s><s xml:id="_qFrXRWu">EuroQol Group.</s><s xml:id="_Q8f6Fc6">EuroQol--a new facility for the measurement of health-related quality of life.</s><s xml:id="_48VDFVz">Health Policy.</s><s xml:id="_bq6wME7">1990;16(3):199-208.</s><s xml:id="_rEzsJTg">doi:10.1016/</s><s xml:id="_faQ3vRf">0168-8510(90)90421-9 133.</s><s xml:id="_HrmXV9C">Ware JE Jr, Sherbourne CD.</s><s xml:id="_hAmeBZj">The MOS 36-item short-form health survey (SF-36).</s><s xml:id="_EQjxYse">I. Conceptual framework and item selection.</s><s xml:id="_vsR5hRm">Med Care.</s><s xml:id="_V4zCjqZ">1992;30 (6):473-483.</s><s xml:id="_eNFPgd5">doi:10.1097/00005650-199206000-00002</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><figDesc><div><p xml:id="_nDaJNd4"><s xml:id="_SwHwxsz">Among all PROMs, only the IPSO 11 Rasch [US English] had sufficient evidence for an A recommendation (recommended for use).</s><s xml:id="_tyBCguP">Six measures received a C rating (not recommended): IPSO-16 [US English], IPSO-10 CTT [US English], PDI [US English], DLQI [Moroccan], IBOP [French and US English], and DLQI [Hungarian].</s><s xml:id="_pxsj4V3">These PROMs had high-quality evidence for an insufficient key measurement property.</s><s xml:id="_mZBDhFf">The remaining PROMs were category B. (eTable 4 in the Supplement)</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Figure 3 .</head><label>3</label><figDesc><div><p xml:id="_fjurA93"><s xml:id="_vXrWFF7">Figure 3. Summary of Content Validity of Dermatology-Specific and Generic Measures</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1 .</head><label>1</label><figDesc><div><p xml:id="_Z9RU7e3"><s xml:id="_9FtJ5Eu">Characteristics of the Psoriasis-Specific Measures</s></p></div></figDesc><table><row><cell>Figure 1. PRISMA Flow Diagram</cell><cell></cell><cell></cell></row><row><cell>2396 Studies from databases/registers</cell><cell></cell><cell></cell></row><row><cell>1483 PubMed</cell><cell></cell><cell></cell></row><row><cell>913 Embase</cell><cell></cell><cell></cell></row><row><cell cols="2">430 References removed</cell><cell></cell></row><row><cell cols="2">430 Duplicates identified by Covidence</cell><cell></cell></row><row><cell>1966 Studies screened</cell><cell></cell><cell></cell></row><row><cell cols="2">1765 Studies excluded</cell><cell></cell></row><row><cell>201 Studies sought for retrieval</cell><cell></cell><cell></cell></row><row><cell cols="2">1 Study not retrieved</cell><cell></cell></row><row><cell cols="2">1 Full text not available</cell><cell></cell></row><row><cell>200 Studies assessed for eligibility</cell><cell></cell><cell></cell></row><row><cell>120 Studies excluded</cell><cell></cell><cell></cell></row><row><cell>6 Duplicate</cell><cell></cell><cell></cell></row><row><cell cols="2">12 Language is not English or Spanish</cell><cell></cell></row><row><cell cols="2">37 Wrong study design</cell><cell></cell></row><row><cell cols="2">27 Not an HRQoL instrument under evaluation</cell><cell></cell></row><row><cell cols="2">13 Wrong patient population</cell><cell></cell></row><row><cell cols="2">1 Study missing relevant data</cell><cell></cell></row><row><cell>1 Abstract only</cell><cell></cell><cell></cell></row><row><cell>80 Studies included in review from</cell><cell></cell><cell></cell></row><row><cell>literature search</cell><cell></cell><cell></cell></row><row><cell>97 Studies included in review</cell><cell>17 Studies included from other sources 17 Citation searching</cell><cell>HRQoL indicates health-related</cell></row><row><cell></cell><cell></cell><cell>quality of life.</cell></row></table><note xml:id="_jp5RtrK"><p><s xml:id="_VTXDhEX">Clinical Review &amp; Education Review Patient-Reported Outcome Measures for Health-Related Quality of Life in Patients With Psoriasis E4 JAMA Dermatology Published online January 24, 2024 (Reprinted) jamadermatology.com</s><s xml:id="_P3HFzBr">fined as any PROM not meeting criteria for an A-level or C-level recommendation.</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Table 1 .</head><label>1</label><figDesc><div><p xml:id="_8AxnHzR"><s xml:id="_btamb7p">Characteristics of the Psoriasis-Specific Measures (continued)</s></p></div></figDesc><table><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Language</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>versions</cell></row><row><cell></cell><cell></cell><cell>Target</cell><cell>Recall</cell><cell>(Sub)scale(s) (No. of</cell><cell></cell><cell></cell><cell>validate in</cell></row><row><cell>PROM</cell><cell>Construct(s)</cell><cell>population</cell><cell>period</cell><cell>items)</cell><cell cols="2">Response options Range of scores</cell><cell>psoriasis</cell></row><row><cell>PSORIQoL 48</cell><cell>Psoriasis-related</cell><cell>Adults with</cell><cell>Not</cell><cell>1 Scale (25)</cell><cell>True/false</cell><cell>0-25</cell><cell>UK English,</cell></row><row><cell></cell><cell>needs-based quality</cell><cell>psoriasis</cell><cell>reported</cell><cell></cell><cell></cell><cell></cell><cell>US English</cell></row><row><cell></cell><cell>of life</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>PQOL-41 95</cell><cell>HRQL</cell><cell>Adults with</cell><cell>4 wk</cell><cell>Emotional (10), body</cell><cell>NA</cell><cell>NA</cell><cell>US English</cell></row><row><cell></cell><cell></cell><cell>psoriasis</cell><cell></cell><cell>image and social</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>acceptability (6), overall</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>psychosocial (6),</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>day-to-day activities</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>(11), day-to-day</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>physical effects (8)</cell><cell></cell><cell></cell><cell></cell></row><row><cell>PQOL-12 95</cell><cell>HRQL, emotional effect,</cell><cell>Adults with</cell><cell>4 wk</cell><cell>Quality of life (8),</cell><cell>0 (Not at all) to</cell><cell>0-120</cell><cell>US English,</cell></row><row><cell></cell><cell>signs/symptoms,</cell><cell>psoriasis</cell><cell></cell><cell>symptoms (4)</cell><cell>10 (very much)</cell><cell></cell><cell>Indian</cell></row><row><cell></cell><cell>functioning (1 item)</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>QLICD-PS</cell><cell>HRQL</cell><cell>Adults with</cell><cell>Not</cell><cell>Physical function (9),</cell><cell>5-Point adjectival</cell><cell>0-100</cell><cell>Chinese</cell></row><row><cell>(V2.0) 46</cell><cell></cell><cell>psoriasis</cell><cell>specified</cell><cell>mental function (11),</cell><cell>scale</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>social function (8),</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>specific</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>symptoms/treatment</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>adverse</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>effects/psychosocial</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>effect of psoriasis (13)</cell><cell></cell><cell></cell><cell></cell></row><row><cell>QualiPso 110</cell><cell>HRQL, assesses role</cell><cell>Adults with</cell><cell>Not</cell><cell>Social life (20), mental</cell><cell>4-Point adjectival</cell><cell>Social life</cell><cell></cell></row><row><cell></cell><cell>functioning, emotional</cell><cell>psoriasis</cell><cell>specified</cell><cell>health (12), treatment</cell><cell>scale</cell><cell>(20-80), mental</cell><cell></cell></row><row><cell></cell><cell>effect, effect of</cell><cell></cell><cell></cell><cell>outcome (4), skin</cell><cell></cell><cell>health (12-48),</cell><cell></cell></row><row><cell></cell><cell>therapy, disease</cell><cell></cell><cell></cell><cell>symptoms (3)</cell><cell></cell><cell>treatment</cell><cell></cell></row><row><cell></cell><cell>signs/symptoms</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>outcomes</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>(4-16), skin</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>symptoms</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>(3-12)</cell><cell></cell></row></table><note xml:id="_rBMFVrH"><p>French</p><p>Abbreviations: BOP, individual burden of psoriasis; EQ-5D-Pso, psoriasis-specific EuroQol 5-dimensional questionnaire; I-HRQL, health-related quality of life; IPBOD, inverse psoriasis burden of disease; IPSO-16, impact of psoriasis questionnaire (16 questions); IPSO-10 CTT, impact of psoriasis questionnaire (10 questions, derived using Classic Test Theory); IPSO-11, Rasch impact of psoriasis questionnaire (11 questions, derived using Rasch methods); NPQ10, nail psoriasis quality of life scale; NA, not available; NAPPA, nail assessment in psoriasis and psoriatic arthritis; NRS, Numeric rating scale; PDI, psoriasis disability index; PLSI, psoriasis life stress inventory; PQLQ, psoriasis quality of life questionnaire; P-SIM, psoriasis impact and symptoms measure; PSORIQoL, psoriasis quality of life scale; PQOL, psoriasis quality of life (41 items); PQOL-12, psoriasis quality of life (12 items); PROM, patient-reported outcome; QLICD-PS (V2.0), psoriasis-specific quality of life instruments for chronic diseases version 2; VAS, visual analogue scale.</p><p>Patient</p><p><s xml:id="_UZ3vDzd">-Reported Outcome Measures for Health-Related Quality of Life in Patients With Psoriasis Review Clinical Review &amp; Education jamadermatology.com</s><s xml:id="_wPnkuep">(Reprinted) JAMA Dermatology Published online January 24, 2024 E5 © 2024 American Medical Association.</s><s xml:id="_qd5GDHr">All rights reserved.</s><s xml:id="_nwZtUP8">Downloaded from jamanetwork.com</s><s xml:id="_q4bhTuf">by Leiden University Libraries user on 04/30/2024</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head>Table 2 .</head><label>2</label><figDesc><div><p><s xml:id="_Kwr65jZ">Characteristics of the Dermatology Specific and Generic MeasuresClinical Review &amp; Education Review Patient-Reported Outcome Measures for Health-Related Quality of Life in Patients With Psoriasis validity studies.</s><s xml:id="_XTNUAMq">The content validity studies for the DLQI (UK English), 50 DLQI (US English), 82 and Skindex-29 (UK English) 50 were of adequate quality, whereas the content validity study for the QOLS (US English) 85 was of inadequate quality.</s><s xml:id="_qtwCkr3">Two SRQOL measures had sufficient overall content validity (DQOL [UK English] 42 and Skindex-16 [US English]</s></p></div></figDesc><table><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Language</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>versions</cell></row><row><cell></cell><cell></cell><cell>Target</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>validate in</cell></row><row><cell>PROM</cell><cell>Constructs</cell><cell>population</cell><cell cols="2">Recall period (Sub)scale(s) (No. of items)</cell><cell cols="2">Response options Range of scores</cell><cell>psoriasis</cell></row><row><cell cols="2">Dermatology specific</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>DLQI 41</cell><cell>SRQL</cell><cell>Patients aged</cell><cell>7 d</cell><cell>1 Scale (10)</cell><cell>4-Point adjectival</cell><cell>0-30</cell><cell>US English, UK</cell></row><row><cell></cell><cell></cell><cell>≥16 y with skin</cell><cell></cell><cell></cell><cell>scale</cell><cell></cell><cell>English,</cell></row><row><cell></cell><cell></cell><cell>disease</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Brazilian,</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Chinese, Dutch,</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Farsi, German,</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Hungarian,</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Italian,</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Norwegian,</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Serbian,</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Spanish,</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Swedish,</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Ukrainian,</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Moroccan</cell></row><row><cell>DQOLS 42</cell><cell>SRQL</cell><cell>Adolescents</cell><cell>Currently</cell><cell>Psychosocial (17), activities (12),</cell><cell cols="2">5-Point adjectival 0-100</cell><cell>UK English</cell></row><row><cell></cell><cell></cell><cell>and adults with</cell><cell></cell><cell>symptoms (12)</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>skin disease</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>FLQA-core 108</cell><cell>SRQL</cell><cell>Adults with skin</cell><cell>1 wk</cell><cell>Physical complaints (7), daily life</cell><cell>5-Point adjectival</cell><cell>Each scale 1-5</cell><cell>German</cell></row><row><cell></cell><cell></cell><cell>diseases</cell><cell></cell><cell>(3), social life (3), mental health</cell><cell>scale</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>situation (9), treatment of skin</cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>disease (3), satisfaction (6)</cell><cell></cell><cell></cell><cell></cell></row><row><cell>ISDL 97</cell><cell>SRQL</cell><cell>Patients aged</cell><cell>Varies by</cell><cell>Physical functioning (9), physical</cell><cell>Physical</cell><cell>Not specified</cell><cell>Dutch</cell></row><row><cell></cell><cell></cell><cell>≥16 y with skin</cell><cell>item, most 4</cell><cell>symptoms (6), scratch response</cell><cell>functioning:</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell>disease</cell><cell>wk</cell><cell>(6), psychological functioning</cell><cell>4-point adjectival</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>(16), stressors (16), illness</cell><cell>scale; physical</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>cognition (18), social support (6)</cell><cell>symptoms:</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>10-cm VAS;</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>scratch response</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>4-point adjectival</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>scale;</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>psychological</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>functioning: 4</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>and 5-point</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>adjectival scales;</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>stressors: 4-point</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>adjectival scale;</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>illness cognitions:</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>4-point adjectival</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>scale; social</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>support: 4-point</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>adjectival scale</cell><cell></cell><cell></cell></row><row><cell>Scalpdex 91</cell><cell>Scalp-disease</cell><cell>Adults with</cell><cell>1 mo</cell><cell>Symptoms (3), emotions (15),</cell><cell>5-Point adjectival</cell><cell>Each domain</cell><cell>Italian</cell></row><row><cell></cell><cell>related HRQL</cell><cell>scalp</cell><cell></cell><cell>functioning (5)</cell><cell>scale</cell><cell>0-100</cell><cell></cell></row><row><cell></cell><cell></cell><cell>dermatoses</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Skindex-16 67</cell><cell>SRQL</cell><cell>Adolescents</cell><cell>1 mo</cell><cell>Symptoms (5), emotions (6),</cell><cell>7-Point adjectival</cell><cell>Each domain</cell><cell>Brazilian, US</cell></row><row><cell></cell><cell></cell><cell>and adults with</cell><cell></cell><cell>functioning (5)</cell><cell>scale</cell><cell>0-100</cell><cell>English,</cell></row><row><cell></cell><cell></cell><cell>skin disease</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Ukrainian</cell></row><row><cell>Skindex-17 94</cell><cell>SRQL</cell><cell>Adolescents</cell><cell>1 mo</cell><cell>Symptoms (5), psychosocial (12)</cell><cell>5-Point adjectival</cell><cell>Symptoms: 0-10;</cell><cell>US English</cell></row><row><cell></cell><cell></cell><cell>and adults with</cell><cell></cell><cell></cell><cell>scale</cell><cell>psychosocial:</cell><cell></cell></row><row><cell></cell><cell></cell><cell>skin disease</cell><cell></cell><cell></cell><cell></cell><cell>0-24</cell><cell></cell></row><row><cell>Skindex-29 93</cell><cell>SRQL</cell><cell>Adolescents</cell><cell>1 mo</cell><cell>Symptoms (10), emotions (7),</cell><cell>5-Point adjectival</cell><cell>Each domain</cell><cell>German,</cell></row><row><cell></cell><cell></cell><cell>and adults with</cell><cell></cell><cell>functioning (12)</cell><cell>scale</cell><cell>0-100</cell><cell>Italian, Polish,</cell></row><row><cell></cell><cell></cell><cell>skin disease</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Spanish, UK</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>English</cell></row><row><cell>Generic</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="2">EQ5D-5d-5L 131 Health state</cell><cell>Adolescents</cell><cell>Today</cell><cell>Mobility (1), self-care (1), usual</cell><cell>5-Point adjectival</cell><cell>The 5 descriptive</cell><cell>UK English,</cell></row><row><cell></cell><cell></cell><cell>and adults</cell><cell></cell><cell>activities (1), pain/discomfort (1),</cell><cell>scale, 100 pt VAS</cell><cell>states are</cell><cell>Chinese, Farsi,</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>anxiety depression (1), health</cell><cell></cell><cell>summarized with</cell><cell>Greek,</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>today VAS</cell><cell></cell><cell>a 5-digit number</cell><cell>Hungarian</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>that describes a</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>health state</cell><cell></cell></row><row><cell cols="2">EQ5D-5d-3L 131,132 Health state</cell><cell>Adolescents</cell><cell>Today</cell><cell>Mobility (1), self-care (1), usual</cell><cell>3-Point adjectival</cell><cell>The 5 descriptive</cell><cell>US English,</cell></row><row><cell></cell><cell></cell><cell>and adults</cell><cell></cell><cell>activities (1), pain/discomfort (1),</cell><cell>scale</cell><cell>states are</cell><cell>Greek,</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>anxiety and/or depression (1),</cell><cell></cell><cell>summarized with</cell><cell>Hungarian,</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>health today VAS</cell><cell></cell><cell>a 5-digit number</cell><cell>Serbian,</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>that describes a</cell><cell>Swedish</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>health state</cell><cell></cell></row><row><cell>EQ VAS 131,132</cell><cell>Health state</cell><cell>Adolescents</cell><cell>Today</cell><cell>Health VAS</cell><cell>0-100 VAS</cell><cell>0-100</cell><cell>US English,</cell></row><row><cell></cell><cell></cell><cell>and adults</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>UK English,</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Greek,</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Hungarian,</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Serbian,</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Swedish,</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Chinese, Farsi</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>(continued)</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_6"><head>Table 2 .</head><label>2</label><figDesc><div><p xml:id="_zxEp6TF"><s xml:id="_CHgKwQB">Characteristics of the Dermatology Specific and Generic Measures (continued) Figure 2. Summary of Content Validity of Psoriasis-Specific Measures</s></p></div></figDesc><table><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>Language</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>versions</cell></row><row><cell></cell><cell></cell><cell>Target</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>validate in</cell></row><row><cell>PROM</cell><cell>Constructs</cell><cell>population</cell><cell cols="3">Recall period (Sub)scale(s) (No. of items)</cell><cell cols="2">Response options Range of scores</cell><cell>psoriasis</cell></row><row><cell>PRISM 57</cell><cell>Having illness</cell><cell>Adults with</cell><cell>Currently</cell><cell cols="2">Distance between illness and self</cell><cell>Measured</cell><cell>0-270</cell><cell>UK English</cell></row><row><cell></cell><cell></cell><cell>chronic illness</cell><cell></cell><cell></cell><cell></cell><cell>distance between</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>2 items</cell><cell></cell></row><row><cell>QOLS 85</cell><cell>Quality of life</cell><cell>Adults</cell><cell>Not</cell><cell>1 Scale (16)</cell><cell></cell><cell>7-Point adjectival</cell><cell>16-112</cell><cell>Norwegian</cell></row><row><cell></cell><cell></cell><cell></cell><cell>specified</cell><cell></cell><cell></cell><cell>scale</cell><cell></cell></row><row><cell>SF-36 133</cell><cell>HRQL</cell><cell>Adolescents</cell><cell>1 mo</cell><cell cols="2">Physical functioning (10), role</cell><cell>Variable</cell><cell>0-100</cell><cell>US English,</cell></row><row><cell></cell><cell></cell><cell>and adults with</cell><cell></cell><cell cols="2">limitations-physical (4), role</cell><cell>adjectival scales</cell><cell></cell><cell>Spanish</cell></row><row><cell></cell><cell></cell><cell>skin disease</cell><cell></cell><cell cols="2">limitations-emotional (3), energy</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="2">(4), emotional well-being (5),</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="2">social functioning (2), pain (2),</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="2">general health (5)</cell><cell></cell><cell></cell></row><row><cell cols="2">WHOQOL-100 96 Quality of life</cell><cell>Adults</cell><cell>Not</cell><cell cols="2">Physical health, psychological,</cell><cell>5-Point adjectival</cell><cell>Each domain</cell><cell>US English</cell></row><row><cell></cell><cell></cell><cell></cell><cell>specified</cell><cell cols="2">level of independence, social</cell><cell>scale</cell><cell>0-100</cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="2">relations, environment,</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="2">spirituality/religion/personal</cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>beliefs (100)</cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="5">Abbreviations: DLQI, Dermatology Life Quality Index; DQOLS, Dermatology</cell><cell cols="4">Pictorial representation of Illness and self-measure; PROM, patient-reported</cell></row><row><cell cols="5">quality of life scales; EQ VAS, EuroQol visual analogue scale; FLQA, Freiburg Life</cell><cell cols="4">outcome measure; QOLS, Quality of Life Scale; SF-36, 36-Item Short Form</cell></row><row><cell cols="5">Quality Assessment; EQ5D-5d-5L, EuroQol 5-dimensional questionnaire (5</cell><cell cols="4">Survey; VAS, visual analogue scale; WHOQOL-100, World Health Organization</cell></row><row><cell cols="5">levels of response); ISDL, Impact of Chronic Skin Disease on Daily Life; PRISM,</cell><cell>Quality of Life.</cell><cell></cell><cell></cell></row></table><note xml:id="_f7ywUhW"><p><s xml:id="_JzKbAeU">Patient-Reported Outcome Measures for Health-Related Quality of Life in Patients With Psoriasis Review Clinical Review &amp; Education jamadermatology.com</s><s xml:id="_mx48bkh">(Reprinted) JAMA Dermatology Published online January 24, 2024 E7 © 2024 American Medical Association.</s><s xml:id="_CDxWBKe">All rights reserved.</s><s xml:id="_wBgkM5C">Downloaded from jamanetwork.com</s><s xml:id="_KNP8xAB">by Leiden University Libraries user on 04/30/2024 lations for several of them.</s><s xml:id="_R8KHYYF">Evaluation of the measurement properties of these identified measures revealed a dearth of information regarding their quality, specifically in terms of key measurement properties such as content validity, structural validity, and internal</s></p></note></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_0"><p xml:id="_vsRPHXf"><s xml:id="_BhNtyCp">JAMA Dermatology Published online January 24, 2024 (Reprinted) jamadermatology.com</s><s xml:id="_dVuE68x">© 2024 American Medical Association.</s><s xml:id="_njVYVXT">All rights reserved.</s><s xml:id="_qSe4byB">Downloaded from jamanetwork.com</s><s xml:id="_xPdYqD2">by Leiden University Libraries user on 04/30/2024</s></p></note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_1"><p xml:id="_8dMMaRP"><s xml:id="_KmR2RmP">© 2024 American Medical Association.</s><s xml:id="_bHNvTVS">All rights reserved.</s><s xml:id="_zhPMHGW">Downloaded from jamanetwork.com</s><s xml:id="_S5tpJKt">by Leiden University Libraries user on 04/30/2024</s></p></note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_2"><p xml:id="_mRJs6DS"><s xml:id="_BMWZqf5">jamadermatology.com (Reprinted) JAMA Dermatology Published online January 24, 2024 E11 © 2024 American Medical Association.</s><s xml:id="_Wuqq7Et">All rights reserved.</s><s xml:id="_BVY5G4d">Downloaded from jamanetwork.com</s><s xml:id="_Nn9bJbg">by Leiden University Libraries user on 04/30/2024</s></p></note>
		</body>
		<back>

			<div type="funding">
<div xml:id="_3dDuuFc"><p xml:id="_Vbvp98p"><s xml:id="_kpH9QKJ"><rs type="person">Dr Pérez-Chada</rs> reported grants from <rs type="funder">National Psoriasis Foundation</rs> and the <rs type="funder">Group for Research and Assessment of Psoriasis and Psoriatic Arthritis</rs> and received honoraria as methodologist from the <rs type="funder">International Dermatology Outcome Measures</rs> outside the submitted work.</s><s xml:id="_7CX9p38"><rs type="person">Dr Hopkins</rs> reported authorship fees from <rs type="funder">Pfizer</rs>, <rs type="funder">Regeneron</rs>, <rs type="funder">Sanofi Genzyme</rs>, <rs type="funder">Sun Pharma</rs>, and <rs type="funder">UCB</rs> outside the submitted work.</s><s xml:id="_MusyRv4"><rs type="person">Dr Strand</rs> reported fees from <rs type="funder">AbbVie</rs>, <rs type="funder">Alpine Immune Sciences</rs>, <rs type="funder">Amgen</rs>, <rs type="funder">AstraZeneca</rs>, <rs type="funder">Bayer</rs>, <rs type="funder">BMS</rs>, <rs type="funder">Boehringer Ingelheim</rs>, submitted work.</s><s xml:id="_5m6xnVH"><rs type="person">Dr Barbieri</rs> reported personal fees from <rs type="institution">Dexcel Pharma</rs> for consulting outside the submitted work.</s><s xml:id="_HZhPUWR">No other disclosures were reported.</s><s xml:id="_bzv6Y78">Funding/Support: Support to use the Covidence platform for abstract screening was provided by <rs type="funder">International Dermatology Outcome Measures (IDEOM)</rs>.</s><s xml:id="_zA4Mczy"><rs type="person">John S Barbieri</rs> is supported by the <rs type="funder">US National Institute of Arthritis and Musculoskeletal and Skin Diseases of the US National Institutes of Health</rs> under award number <rs type="grantNumber">1K23AR078930</rs>.</s></p><p xml:id="_5h2Zzdq"><s xml:id="_Vrv324x">Role of the Funder/Sponsor: <rs type="projectName">International Dermatology Outcome Measures</rs> had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.</s></p></div>
			</div>
			<listOrg type="funding">
				<org type="funding" xml:id="_AKAsahp">
					<idno type="grant-number">1K23AR078930</idno>
				</org>
				<org type="funded-project" xml:id="_dJcf7nd">
					<orgName type="project" subtype="full">International Dermatology Outcome Measures</orgName>
				</org>
			</listOrg>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main" xml:id="_4HQAm6W">The COMET Handbook: version 1.0</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">R</forename><surname>Williamson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">G</forename><surname>Altman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Bagley</surname></persName>
		</author>
		<idno type="DOI">10.1186/s13063-017-1978-4</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_v6pnnyV">Trials</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="issue">suppl 3</biblScope>
			<biblScope unit="page">280</biblScope>
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Williamson PR, Altman DG, Bagley H, et al. The COMET Handbook: version 1.0. Trials. 2017;18(suppl 3):280. doi:10.1186/s13063-017-1978-4</note>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main" xml:id="_AWA2bxH">Identifying a core domain set to assess psoriasis in clinical trials</title>
		<author>
			<persName><forename type="first">Callis</forename><surname>Duffin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Merola</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Christensen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename></persName>
		</author>
		<idno type="DOI">10.1001/jamadermatol.2018.1165?utm_campaign=articlePDF%26utm_medium=articlePDFlink%26utm_source=articlePDF%26utm_content=jamadermatol.2023.5439</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_yPGzZgR">JAMA Dermatol</title>
		<imprint>
			<biblScope unit="volume">154</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="1137" to="1144" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Callis Duffin K, Merola JF, Christensen R, et al. Identifying a core domain set to assess psoriasis in clinical trials. JAMA Dermatol. 2018;154(10):1137-1144. doi:10.1001/jamadermatol.2018.1165</note>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main" xml:id="_Mzm8v7a">Measuring quality of life: apparent benefits, potential concerns</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Till</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_9bnnV36">Can J Oncol</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="243" to="248" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Till JE. Measuring quality of life: apparent benefits, potential concerns. Can J Oncol. 1994;4 (1):243-248.</note>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main" xml:id="_4M3Sf5D">Measuring patient-reported outcomes: moving beyond misplaced common sense to hard science</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">P</forename><surname>Mckenna</surname></persName>
		</author>
		<idno type="DOI">10.1186/1741-7015-9-86</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_NFrUpUP">BMC Med</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page">86</biblScope>
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
	<note type="raw_reference">McKenna SP. Measuring patient-reported outcomes: moving beyond misplaced common sense to hard science. BMC Med. 2011;9:86. doi:10. 1186/1741-7015-9-86</note>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main" xml:id="_5Zpr9hz">Linking clinical variables with health-related quality of life. a conceptual model of patient outcomes</title>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">B</forename><surname>Wilson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">D</forename><surname>Cleary</surname></persName>
		</author>
		<idno type="DOI">10.1001/jama.1995.03520250075037?utm_campaign=articlePDF%26utm_medium=articlePDFlink%26utm_source=articlePDF%26utm_content=jamadermatol.2023.5439</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_9qD8T9y">JAMA</title>
		<imprint>
			<biblScope unit="volume">273</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="59" to="65" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Wilson IB, Cleary PD. Linking clinical variables with health-related quality of life. a conceptual model of patient outcomes. JAMA. 1995;273(1):59- 65. doi:10.1001/jama.1995.03520250075037</note>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main" xml:id="_J5cuXHr">Pathological worrying, illness perceptions and disease severity in patients with psoriasis</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">G</forename><surname>Fortune</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">L</forename><surname>Richards</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Main</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Cem</forename><surname>Griffiths</surname></persName>
		</author>
		<idno type="DOI">10.1348/135910700168775</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_AU3N5ee">Br J Health Psychol</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="71" to="82" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Fortune DG, Richards HL, Main CJ, Griffiths CEM. Pathological worrying, illness perceptions and disease severity in patients with psoriasis. Br J Health Psychol. 2000;5(Part 1):71-82. doi:10.1348/ 135910700168775</note>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main" xml:id="_RY2CzyM">Psychological stress, distress and disability in patients with psoriasis: consensus and variation in the contribution of illness perceptions, coping and alexithymia</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">G</forename><surname>Fortune</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">L</forename><surname>Richards</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">E</forename><surname>Griffiths</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Main</surname></persName>
		</author>
		<idno type="DOI">10.1348/014466502163949</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_fWyR8m8">Br J Clin Psychol</title>
		<imprint>
			<biblScope unit="volume">41</biblScope>
			<biblScope unit="issue">Pt 2</biblScope>
			<biblScope unit="page" from="157" to="174" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Fortune DG, Richards HL, Griffiths CE, Main CJ. Psychological stress, distress and disability in patients with psoriasis: consensus and variation in the contribution of illness perceptions, coping and alexithymia. Br J Clin Psychol. 2002;41(Pt 2):157-174. doi:10.1348/014466502163949</note>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main" xml:id="_nJwFuWC">Quality-of-life instruments: evaluation of the impact of psoriasis on patients</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Heller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Wong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">V</forename><surname>Nguyen</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.det.2011.11.006</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_CsqJHjD">Dermatol Clin</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="281" to="291" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Heller MM, Wong JW, Nguyen TV, et al. Quality-of-life instruments: evaluation of the impact of psoriasis on patients. Dermatol Clin. 2012;30(2):281-291, ix. doi:10.1016/j.det.2011.11.006</note>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main" xml:id="_65wpNAM">The burden of moderate to severe psoriasis: an overview</title>
		<author>
			<persName><forename type="first">G</forename><surname>Raho</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Koleva</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Garattini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Naldi</surname></persName>
		</author>
		<idno type="DOI">10.2165/11591580-000000000-00000</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_eWhK7jt">Pharmacoeconomics</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="1005" to="1013" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Raho G, Koleva DM, Garattini L, Naldi L. The burden of moderate to severe psoriasis: an overview. Pharmacoeconomics. 2012;30(11):1005- 1013. doi:10.2165/11591580-000000000-00000</note>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main" xml:id="_DEee42v">Impact of psoriasis on quality of life: a qualitative study focused on patient perspectives</title>
		<author>
			<persName><forename type="first">E</forename><surname>Schoenberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">V</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Keller</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_xs2ecbX">Skinmed</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="438" to="439" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Schoenberg E, Wang JV, Keller M. Impact of psoriasis on quality of life: a qualitative study focused on patient perspectives. Skinmed. 2021;19 (6):438-439.</note>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main" xml:id="_bPyHsa9">Effects of disease severity on quality of life in patients with psoriasis</title>
		<author>
			<persName><forename type="first">Yavuz</forename><surname>Daglioglu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">B</forename><surname>Cadirci</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Aksoy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename></persName>
		</author>
		<idno type="DOI">10.1111/dth.14422</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_a6c5JUJ">Dermatol Ther</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page">14422</biblScope>
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Yavuz Daglioglu EB, Cadirci D, Aksoy M. Effects of disease severity on quality of life in patients with psoriasis. Dermatol Ther. 2020;33(6):e14422. doi: 10.1111/dth.14422</note>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main" xml:id="_2FnMWN9">The applications of PROs in clinical practice: what are they, do they work, and why?</title>
		<author>
			<persName><forename type="first">J</forename><surname>Greenhalgh</surname></persName>
		</author>
		<idno type="DOI">10.1007/s11136-008-9430-6</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_CxWHUyq">Qual Life Res</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="115" to="123" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Greenhalgh J. The applications of PROs in clinical practice: what are they, do they work, and why? Qual Life Res. 2009;18(1):115-123. doi:10.1007/ s11136-008-9430-6</note>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main" xml:id="_pndP2jG">How do patient reported outcome measures (PROMs) support clinician-patient communication and patient care? A realist synthesis</title>
		<author>
			<persName><forename type="first">J</forename><surname>Greenhalgh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Gooding</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Gibbons</surname></persName>
		</author>
		<idno type="DOI">10.1186/s41687-018-0061-6</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_3vhbpQp">J Patient Rep Outcomes</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page">42</biblScope>
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Greenhalgh J, Gooding K, Gibbons E, et al. How do patient reported outcome measures (PROMs) support clinician-patient communication and patient care? A realist synthesis. J Patient Rep Outcomes. 2018;2:42. doi:10.1186/s41687-018- 0061-6</note>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main" xml:id="_4ag8zMs">Patient-reported outcome measures as complementary information to clinician-reported outcome measures in patients with psoriasis</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Barbieri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Gelfand</surname></persName>
		</author>
		<idno type="DOI">10.1001/jamadermatol.2021.3341?utm_campaign=articlePDF%26utm_medium=articlePDFlink%26utm_source=articlePDF%26utm_content=jamadermatol.2023.5439</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_u8gSbgn">JAMA Dermatol</title>
		<imprint>
			<biblScope unit="volume">157</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="1236" to="1237" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Barbieri JS, Gelfand JM. Patient-reported outcome measures as complementary information to clinician-reported outcome measures in patients with psoriasis. JAMA Dermatol. 2021;157(10):1236- 1237. doi:10.1001/jamadermatol.2021.3341</note>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main" xml:id="_SJJrQDW">Achieving consensus on patient-reported outcome measures in clinical practice for inflammatory skin disorders</title>
		<author>
			<persName><forename type="first">L</forename><surname>Perez-Chada</surname></persName>
			<affiliation>
				<orgName type="collaboration">American Academy of Dermatology</orgName>
			</affiliation>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">L</forename><surname>Taliercio</surname></persName>
			<affiliation>
				<orgName type="collaboration">American Academy of Dermatology</orgName>
			</affiliation>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">B</forename><surname>Gottlieb</surname></persName>
			<affiliation>
				<orgName type="collaboration">American Academy of Dermatology</orgName>
			</affiliation>
		</author>
		<idno type="DOI">10.1016/j.jaad.2019.09.008</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_UK38TJt">J Am Acad Dermatol</title>
		<imprint>
			<biblScope unit="volume">88</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="86" to="93" />
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Perez-Chada L, Taliercio VL, Gottlieb AB, et al; International Dermatology Outcome Measures; American Academy of Dermatology. Achieving consensus on patient-reported outcome measures in clinical practice for inflammatory skin disorders. J Am Acad Dermatol. 2023;88(1):86-93. doi:10. 1016/j.jaad.2019.09.008</note>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main" xml:id="_PDQWTQj">EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris -Part 1: treatment and monitoring recommendations</title>
		<author>
			<persName><forename type="first">A</forename><surname>Nast</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Smith</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">I</forename><surname>Spuls</surname></persName>
		</author>
		<idno type="DOI">10.1111/jdv.16915</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_UjZfUps">J Eur Acad Dermatol Venereol</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="2461" to="2498" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Nast A, Smith C, Spuls PI, et al. EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris -Part 1: treatment and monitoring recommendations. J Eur Acad Dermatol Venereol. 2020;34(11):2461-2498. doi:10.1111/jdv.16915</note>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main" xml:id="_6mcv9XY">Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Elmets</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">L</forename><surname>Leonardi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Dmr</forename><surname>Davis</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.jaad.2018.11.058</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_Es5nvXp">J Am Acad Dermatol</title>
		<imprint>
			<biblScope unit="volume">80</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="1073" to="1113" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Elmets CA, Leonardi CL, Davis DMR, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. J Am Acad Dermatol. 2019;80(4):1073-1113. doi:10.1016/j.jaad.2018.11.058</note>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main" xml:id="_y9ppNSG">Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics</title>
		<author>
			<persName><forename type="first">A</forename><surname>Menter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">E</forename><surname>Strober</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">H</forename><surname>Kaplan</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.jaad.2018.11.057</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_8ycqzuB">J Am Acad Dermatol</title>
		<imprint>
			<biblScope unit="volume">80</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="1029" to="1072" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029-1072. doi:10.1016/j. jaad.2018.11.057</note>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main" xml:id="_HVPjsdf">COSMIN guideline for systematic reviews of patient-reported outcome measures</title>
		<author>
			<persName><forename type="first">Cac</forename><surname>Prinsen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">B</forename><surname>Mokkink</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Bouter</surname></persName>
		</author>
		<idno type="DOI">10.1007/s11136-018-1798-3</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_HpbSEUN">Qual Life Res</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="1147" to="1157" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Prinsen CAC, Mokkink LB, Bouter LM, et al. COSMIN guideline for systematic reviews of patient-reported outcome measures. Qual Life Res. 2018;27(5):1147-1157. doi:10.1007/s11136-018-1798-3</note>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main" xml:id="_4Tx5HAq">COSMIN Risk of Bias checklist for systematic reviews of Patient-Reported Outcome Measures</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">B</forename><surname>Mokkink</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Hcw</forename><surname>Vet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Cac</forename><surname>Prinsen</surname></persName>
		</author>
		<idno type="DOI">10.1007/s11136-017-1765-4</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_GvUUbY9">Qual Life Res</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="1171" to="1179" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Mokkink LB, de Vet HCW, Prinsen CAC, et al. COSMIN Risk of Bias checklist for systematic reviews of Patient-Reported Outcome Measures. Qual Life Res. 2018;27(5):1171-1179. doi:10.1007/ s11136-017-1765-4</note>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main" xml:id="_2dby74M">COSMIN methodology for evaluating the content validity of patient-reported outcome measures: a Delphi study</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">B</forename><surname>Terwee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Cac</forename><surname>Prinsen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Chiarotto</surname></persName>
		</author>
		<idno type="DOI">10.1007/s11136-018-1829-0</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_8eUWfJ7">Qual Life Res</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="1159" to="1170" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Terwee CB, Prinsen CAC, Chiarotto A, et al. COSMIN methodology for evaluating the content validity of patient-reported outcome measures: a Delphi study. Qual Life Res. 2018;27(5):1159-1170. doi:10.1007/s11136-018-1829-0</note>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main" xml:id="_ktCgjRX">Knowledge as a formative construct: a good alpha is not always better</title>
		<author>
			<persName><forename type="first">M</forename><surname>Stadler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Sailer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Fischer</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.newideapsych.2020.100832</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_mMB9VN7">New Ideas in Psychology</title>
		<imprint>
			<biblScope unit="volume">60</biblScope>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Stadler M, Sailer M, Fischer F. Knowledge as a formative construct: a good alpha is not always better. New Ideas in Psychology. 2021;60. doi:10. 1016/j.newideapsych.2020.100832</note>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main" xml:id="_puzHDhY">Factor analysis, causal indicators and quality of life</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">M</forename><surname>Fayers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Hand</surname></persName>
		</author>
		<idno type="DOI">10.1023/a:1026490117121</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_FX7TGGd">Qual Life Res</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="139" to="150" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Fayers PM, Hand DJ. Factor analysis, causal indicators and quality of life. Qual Life Res. 1997;6 (2):139-150. doi:10.1023/A:1026490117121</note>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main" xml:id="_RcDsTqh">Two kinds of items in quality of life instruments: &apos;indicator and causal variables&apos; in the EORTC qlq-c30</title>
		<author>
			<persName><forename type="first">S</forename><surname>Boehmer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Luszczynska</surname></persName>
		</author>
		<idno type="DOI">10.1007/s11136-005-8290-6</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_NnbZrkM">Qual Life Res</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="131" to="141" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Boehmer S, Luszczynska A. Two kinds of items in quality of life instruments: &apos;indicator and causal variables&apos; in the EORTC qlq-c30. Qual Life Res. 2006;15(1):131-141. doi:10.1007/s11136-005-8290-6</note>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main" xml:id="_NFcJasJ">Development of needs-based quality of life instruments</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">P</forename><surname>Mckenna</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">C</forename><surname>Doward</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Niero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Erdman</surname></persName>
		</author>
		<idno type="DOI">10.1111/j.1524-4733.2004.7s105.x</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_xHF3CAg">Value Health</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="issue">suppl 1</biblScope>
			<biblScope unit="page" from="17" to="S21" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
	<note type="raw_reference">McKenna SP, Doward LC, Niero M, Erdman R. Development of needs-based quality of life instruments. Value Health. 2004;7(suppl 1):S17-S21. doi:10.1111/j.1524-4733.2004.7s105.x</note>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main" xml:id="_jMzTYGY">A detailed analysis of &apos;not relevant&apos; responses on the DLQI in psoriasis: potential biases in treatment decisions</title>
		<author>
			<persName><forename type="first">F</forename><surname>Rencz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">K</forename><surname>Poór</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Péntek</surname></persName>
		</author>
		<idno type="DOI">10.1111/jdv.14676</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_deHF6z2">J Eur Acad Dermatol Venereol</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="783" to="790" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Rencz F, Poór AK, Péntek M, et al. A detailed analysis of &apos;not relevant&apos; responses on the DLQI in psoriasis: potential biases in treatment decisions. J Eur Acad Dermatol Venereol. 2018;32(5):783-790. doi:10.1111/jdv.14676</note>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main" xml:id="_vvMB2T5">A qualitative investigation of the relevance of skin irritation and self-confidence bolt-ons and their conceptual overlap with the EQ-5D in patients with psoriasis</title>
		<author>
			<persName><forename type="first">F</forename><surname>Rencz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Mukuria</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bató</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">K</forename><surname>Poór</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">P</forename><surname>Finch</surname></persName>
		</author>
		<idno type="DOI">10.1007/s11136-022-03141-y</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_bhHxVTx">Qual Life Res</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="3049" to="3060" />
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Rencz F, Mukuria C, Bató A, Poór AK, Finch AP. A qualitative investigation of the relevance of skin irritation and self-confidence bolt-ons and their conceptual overlap with the EQ-5D in patients with psoriasis. Qual Life Res. 2022;31(10):3049-3060. doi:10.1007/s11136-022-03141-y</note>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main" xml:id="_3eukjM5">A Rasch model analysis of two interpretations of &apos;not relevant&apos; responses on the Dermatology Life Quality Index (DLQI)</title>
		<author>
			<persName><forename type="first">F</forename><surname>Rencz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">Z</forename><surname>Mitev</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Á</forename><surname>Szabó</surname></persName>
		</author>
		<idno type="DOI">10.1007/s11136-021-02803-7</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_uy7he27">Qual Life Res</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="2375" to="2386" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Rencz F, Mitev AZ, Szabó Á, et al. A Rasch model analysis of two interpretations of &apos;not relevant&apos; responses on the Dermatology Life Quality Index (DLQI). Qual Life Res. 2021;30(8): 2375-2386. doi:10.1007/s11136-021-02803-7</note>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main" xml:id="_DPp8WAa">A research approach to improving our quality of life</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Flanagan</surname></persName>
		</author>
		<idno type="DOI">10.1037/0003-066x.33.2.138</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_P7huy2E">Am Psychol</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="138" to="147" />
			<date type="published" when="1978">1978</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Flanagan JC. A research approach to improving our quality of life. Am Psychol. 1978;33(2):138-147. doi:10.1037/0003-066X.33.2.138</note>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main" xml:id="_nwEJwMX">Analysis of three outcome measures in moderate to severe psoriasis: a registry-based study of 2450 patients</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Norlin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Steen Carlsson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Persson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Schmitt-Egenolf</surname></persName>
		</author>
		<idno type="DOI">10.1111/j.1365-2133.2011.10778.x</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_2qTSmwp">Br J Dermatol</title>
		<imprint>
			<biblScope unit="volume">166</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="797" to="802" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Norlin JM, Steen Carlsson K, Persson U, Schmitt-Egenolf M. Analysis of three outcome measures in moderate to severe psoriasis: a registry-based study of 2450 patients. Br J Dermatol. 2012;166(4):797-802. doi:10.1111/j.1365- 2133.2011.10778.x</note>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main" xml:id="_AEr8FhM">Assessing illness-related stress in psoriasis: the psychometric properties of the Psoriasis Life Stress Inventory</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">G</forename><surname>Fortune</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Main</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O'</forename><surname>Sullivan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">M</forename><surname>Griffiths</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">E</forename></persName>
		</author>
		<idno type="DOI">10.1016/S0022-3999(97)00036-6</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_vyZV4VA">J Psychosom Res</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="467" to="475" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Fortune DG, Main CJ, O&apos;Sullivan TM, Griffiths CE. Assessing illness-related stress in psoriasis: the psychometric properties of the Psoriasis Life Stress Inventory. J Psychosom Res. 1997;42(5):467-475. doi:10.1016/S0022-3999(97)00036-6</note>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main" xml:id="_9b8RFGx">Assessment of the psychometric properties of the EQ-5D-3L and EQ-5D-5L instruments in psoriasis</title>
		<author>
			<persName><forename type="first">J</forename><surname>Yfantopoulos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Chantzaras</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kontodimas</surname></persName>
		</author>
		<idno type="DOI">10.1007/s00403-017-1743-2</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_EAfyRzD">Arch Dermatol Res</title>
		<imprint>
			<biblScope unit="volume">309</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="357" to="370" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Yfantopoulos J, Chantzaras A, Kontodimas S. Assessment of the psychometric properties of the EQ-5D-3L and EQ-5D-5L instruments in psoriasis. Arch Dermatol Res. 2017;309(5):357-370. doi:10. 1007/s00403-017-1743-2</note>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main" xml:id="_yWBnyYF">Comparing the impact of psoriasis and atopic dermatitis on quality of life: co-calibration of the PSORIQoL and QoLIAD</title>
		<author>
			<persName><forename type="first">J</forename><surname>Twiss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">P</forename><surname>Mckenna</surname></persName>
		</author>
		<idno type="DOI">10.1007/s11136-014-0630-y</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_UPCdjAD">Qual Life Res</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="105" to="113" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Twiss J, McKenna SP. Comparing the impact of psoriasis and atopic dermatitis on quality of life: co-calibration of the PSORIQoL and QoLIAD. Qual Life Res. 2015;24(1):105-113. doi:10.1007/s11136- 014-0630-y</note>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main" xml:id="_ZnvmmjQ">Comparison of quality of life questionnaires and their correlation with the clinical course of patients with psoriasis</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Torres</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Silva</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">F</forename><surname>Magalhães</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Morcillo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">E</forename><surname>Velho</surname></persName>
		</author>
		<idno type="DOI">10.1590/s0365-05962011000100005</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_wPZpQy8">An Bras Dermatol</title>
		<imprint>
			<biblScope unit="volume">86</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="45" to="49" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Torres RA, Silva SA, Magalhães RF, Morcillo AM, Velho PE. Comparison of quality of life questionnaires and their correlation with the clinical course of patients with psoriasis. An Bras Dermatol. 2011;86(1):45-49. doi:10.1590/S0365- 05962011000100005</note>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main" xml:id="_m2Fxjfn">Comparison of Skindex-29, Dermatology Life Quality Index, Psoriasis Disability Index and Medical Outcome Study Short Form 36 in patients with mild to severe psoriasis</title>
		<author>
			<persName><forename type="first">P</forename><surname>Fernandez-Peñas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Jones-Caballero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Espallardo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>García-Díez</surname></persName>
		</author>
		<idno type="DOI">10.1111/j.1365-2133.2012.10806.x</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_tGsDna6">Br J Dermatol</title>
		<imprint>
			<biblScope unit="volume">166</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="884" to="887" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Fernandez-Peñas P, Jones-Caballero M, Espallardo O, García-Díez A. Comparison of Skindex-29, Dermatology Life Quality Index, Psoriasis Disability Index and Medical Outcome Study Short Form 36 in patients with mild to severe psoriasis. Br J Dermatol. 2012;166(4):884-887. doi: 10.1111/j.1365-2133.2012.10806.x</note>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main" xml:id="_FMKsm7G">Can we rely on the Dermatology Life Quality Index as a measure of the impact of psoriasis or atopic dermatitis?</title>
		<author>
			<persName><forename type="first">J</forename><surname>Twiss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Meads</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">P</forename><surname>Preston</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Crawford</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">P</forename><surname>Mckenna</surname></persName>
		</author>
		<idno type="DOI">10.1038/jid.2011.238</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_swC6BCB">J Invest Dermatol</title>
		<imprint>
			<biblScope unit="volume">132</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="76" to="84" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Twiss J, Meads DM, Preston EP, Crawford SR, McKenna SP. Can we rely on the Dermatology Life Quality Index as a measure of the impact of psoriasis or atopic dermatitis? J Invest Dermatol. 2012;132(1):76-84. doi:10.1038/jid.2011.238</note>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main" xml:id="_7ku3uju">Characterization of patient-reported outcomes in moderate to severe psoriasis</title>
		<author>
			<persName><forename type="first">S</forename><surname>Krenzer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Radtke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Schmitt-Rau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Augustin</forename><forename type="middle">M</forename></persName>
		</author>
		<idno type="DOI">10.1159/000330560</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_4HMsgY4">Dermatology</title>
		<imprint>
			<biblScope unit="volume">223</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="80" to="86" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Krenzer S, Radtke M, Schmitt-Rau K, Augustin M. Characterization of patient-reported outcomes in moderate to severe psoriasis. Dermatology. 2011; 223(1):80-86. doi:10.1159/000330560</note>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main" xml:id="_pWsmmHT">Correlation between Dermatology Life Quality Index and Psoriasis Area and Severity Index in patients with psoriasis treated with ustekinumab</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Hesselvig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Egeberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">D</forename><surname>Loft</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Zachariae</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Kofoed</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Skov</surname></persName>
		</author>
		<idno type="DOI">10.2340/00015555-2833</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_duxDPvn">Acta Derm Venereol</title>
		<imprint>
			<biblScope unit="volume">98</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="335" to="339" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Hesselvig JH, Egeberg A, Loft ND, Zachariae C, Kofoed K, Skov L. Correlation between Dermatology Life Quality Index and Psoriasis Area and Severity Index in patients with psoriasis treated with ustekinumab. Acta Derm Venereol. 2018;98 (3):335-339. doi:10.2340/00015555-2833</note>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main" xml:id="_4htHheX">Cross-cultural inequivalence of dermatologyspecific health-related quality of life instruments in psoriasis patients</title>
		<author>
			<persName><forename type="first">T</forename><surname>Nijsten</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Meads</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>De Korte</surname></persName>
		</author>
		<idno type="DOI">10.1038/sj.jid.5700875</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_wQSkPFD">J Invest Dermatol</title>
		<imprint>
			<biblScope unit="volume">127</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="2315" to="2322" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Nijsten T, Meads DM, de Korte J, et al. Cross-cultural inequivalence of dermatology- specific health-related quality of life instruments in psoriasis patients. J Invest Dermatol. 2007;127 (10):2315-2322. doi:10.1038/sj.jid.5700875</note>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main" xml:id="_h9rXUQ7">Psoriasis-an index of disability</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">Y</forename><surname>Finlay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">E</forename><surname>Kelly</surname></persName>
		</author>
		<idno type="DOI">10.1111/j.1365-2230.1987.tb01844.x</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_Tq3cmAx">Clin Exp Dermatol</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="8" to="11" />
			<date type="published" when="1987">1987</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Finlay AY, Kelly SE. Psoriasis-an index of disability. Clin Exp Dermatol. 1987;12(1):8-11. doi:10. 1111/j.1365-2230.1987.tb01844.x</note>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main" xml:id="_KF34FCZ">Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">Y</forename><surname>Finlay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">K</forename><surname>Khan</surname></persName>
		</author>
		<idno type="DOI">10.1111/j.1365-2230.1994.tb01167.x</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_4Cz7Nsz">Clin Exp Dermatol</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="210" to="216" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210-216. doi:10.1111/j.1365-2230.1994.tb01167.x</note>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main" xml:id="_WPbrFA2">Dermatology quality of life scales-a measure of the impact of skin diseases</title>
		<author>
			<persName><forename type="first">M</forename><surname>Morgan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Mccreedy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Simpson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Hay</surname></persName>
		</author>
		<idno type="DOI">10.1111/j.1365-2133.1997.tb14896.x</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_B5JnhcF">Br J Dermatol</title>
		<imprint>
			<biblScope unit="volume">136</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="202" to="206" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Morgan M, McCreedy R, Simpson J, Hay RJ. Dermatology quality of life scales-a measure of the impact of skin diseases. Br J Dermatol. 1997;136 (2):202-206.</note>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main" xml:id="_jwfCWAz">Developing a quality of life instrument in patients with psoriasis: the Psoriasis of Life Questionnaire (PQLQ)</title>
		<author>
			<persName><forename type="first">I</forename><surname>Inanir</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Aydemir</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Gündüz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">E</forename><surname>Danaci</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Türel</surname></persName>
		</author>
		<idno type="DOI">10.1111/j.1365-4632.2005.02448.x</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_uQnxaD8">Int J Dermatol</title>
		<imprint>
			<biblScope unit="volume">45</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="234" to="238" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Inanir I, Aydemir O, Gündüz K, Danaci AE, Türel A. Developing a quality of life instrument in patients with psoriasis: the Psoriasis of Life Questionnaire (PQLQ). Int J Dermatol. 2006;45(3): 234-238. doi:10.1111/j.1365-4632.2005.02448.x</note>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main" xml:id="_APZpFVz">Development and Content Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM) for Assessment of Plaque Psoriasis</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">B</forename><surname>Gottlieb</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Ciaravino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Cioffi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Peterson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">B</forename><surname>Warren</surname></persName>
		</author>
		<idno type="DOI">10.1007/s13555-020-00434-3</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_ARSUB5n">Dermatol Ther (Heidelb)</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="1255" to="1272" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Gottlieb AB, Ciaravino V, Cioffi C, Peterson L, Warren RB. Development and Content Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM) for Assessment of Plaque Psoriasis. Dermatol Ther (Heidelb). 2020;10(6):1255-1272. doi:10.1007/s13555-020-00434-3</note>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main" xml:id="_hhkN7Zf">Development and validation of nail psoriasis quality of life scale (NPQ10)</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Ortonne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Baran</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Corvest</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Schmitt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Voisard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Taieb</surname></persName>
		</author>
		<idno type="DOI">10.1111/j.1468-3083.2009.03344.x</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_K8erNjj">J Eur Acad Dermatol Venereol</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="22" to="27" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Ortonne JP, Baran R, Corvest M, Schmitt C, Voisard JJ, Taieb C. Development and validation of nail psoriasis quality of life scale (NPQ10). J Eur Acad Dermatol Venereol. 2010;24(1):22-27. doi:10. 1111/j.1468-3083.2009.03344.x</note>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main" xml:id="_pZAjKc4">Development and validation of the psoriasis scale among the system of quality of life instruments for chronic diseases QLICD-PS (V2.0)</title>
		<author>
			<persName><forename type="first">Q</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Feng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Wan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Tan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Yu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Wang</surname></persName>
		</author>
		<idno type="DOI">10.1186/s12955-022-01970-6</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_k3TgRTz">Health Qual Life Outcomes</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page">68</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Liu Q, Feng L, Wan C, Tan J, Yu J, Wang L. Development and validation of the psoriasis scale among the system of quality of life instruments for chronic diseases QLICD-PS (V2.0). Health Qual Life Outcomes. 2022;20(1):68. doi:10.1186/s12955-022- 01970-6</note>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main" xml:id="_ggnzAYy">Development of a disease-specific version of the EQ-5D-5L for use in patients suffering from psoriasis: lessons learned from a feasibility study in the UK</title>
		<author>
			<persName><forename type="first">P</forename><surname>Swinburn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Lloyd</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">S</forename><surname>Boye</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Edson-Heredia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Bowman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Janssen</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.jval.2013.10.003</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_zc6RyDA">Value Health</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="1156" to="1162" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Swinburn P, Lloyd A, Boye KS, Edson-Heredia E, Bowman L, Janssen B. Development of a disease-specific version of the EQ-5D-5L for use in patients suffering from psoriasis: lessons learned from a feasibility study in the UK. Value Health. 2013;16(8):1156-1162. doi:10.1016/j.jval.2013.10.003</note>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main" xml:id="_2fKzGJx">Development of the PSORIQoL, a psoriasis-specific measure of quality of life designed for use in clinical practice and trials</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">P</forename><surname>Mckenna</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Cook</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Whalley</surname></persName>
		</author>
		<idno type="DOI">10.1046/j.1365-2133.2003.05492.x</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_UU5bjVZ">Br J Dermatol</title>
		<imprint>
			<biblScope unit="volume">149</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="323" to="331" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
	<note type="raw_reference">McKenna SP, Cook SA, Whalley D, et al. Development of the PSORIQoL, a psoriasis-specific measure of quality of life designed for use in clinical practice and trials. Br J Dermatol. 2003;149(2): 323-331. doi:10.1046/j.1365-2133.2003.05492.x</note>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main" xml:id="_MZrhvQ8">Development of the US PSORIQoL: a psoriasis-specific measure of quality of life</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">P</forename><surname>Mckenna</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Lebwohl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">N</forename><surname>Kahler</surname></persName>
		</author>
		<idno type="DOI">10.1111/j.1365-4632.2005.01941.x</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_7WGwVxE">Int J Dermatol</title>
		<imprint>
			<biblScope unit="volume">44</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="462" to="469" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
	<note type="raw_reference">McKenna SP, Lebwohl M, Kahler KN. Development of the US PSORIQoL: a psoriasis-specific measure of quality of life. Int J Dermatol. 2005;44(6):462-469. doi:10.1111/j.1365- 4632.2005.01941.x</note>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main" xml:id="_sAh5JzT">DLQI Seems to be &apos;Action&apos;, and Skindex-29 Seems to be &apos;Emotion&apos;&quot;: qualitative study of the perceptions of patients with psoriasis or eczema on two common dermatology-specific quality of life measures</title>
		<author>
			<persName><forename type="first">P</forename><surname>Paudyal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Apfelbacher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Jones</surname></persName>
		</author>
		<idno type="DOI">10.2340/00015555-3417</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_6hjF2PK">Acta Derm Venereol</title>
		<imprint>
			<biblScope unit="volume">100</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page">105</biblScope>
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Paudyal P, Apfelbacher C, Jones C, et al. &quot;DLQI Seems to be &apos;Action&apos;, and Skindex-29 Seems to be &apos;Emotion&apos;&quot;: qualitative study of the perceptions of patients with psoriasis or eczema on two common dermatology-specific quality of life measures. Acta Derm Venereol. 2020;100(8):adv00105. doi:10. 2340/00015555-3417</note>
</biblStruct>

<biblStruct xml:id="b50">
	<analytic>
		<title level="a" type="main" xml:id="_6bTAv7H">DLQI-R scoring improves the discriminatory power of the Dermatology Life Quality Index in patients with psoriasis, pemphigus and morphea</title>
		<author>
			<persName><forename type="first">F</forename><surname>Rencz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Gulácsi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Péntek</surname></persName>
		</author>
		<idno type="DOI">10.1111/bjd.18435</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_uHyFgSU">Br J Dermatol</title>
		<imprint>
			<biblScope unit="volume">182</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="1167" to="1175" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Rencz F, Gulácsi L, Péntek M, et al. DLQI-R scoring improves the discriminatory power of the Dermatology Life Quality Index in patients with psoriasis, pemphigus and morphea. Br J Dermatol. 2020;182(5):1167-1175. doi:10.1111/bjd.18435</note>
</biblStruct>

<biblStruct xml:id="b51">
	<analytic>
		<title level="a" type="main" xml:id="_zfc5Zrp">Does the choice of tariff matter? A comparison of EQ-5D-5L utility scores using Chinese, UK, and Japanese tariffs on patients with psoriasis vulgaris in Central South China</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Zhao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">P</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Chen</surname></persName>
		</author>
		<idno type="DOI">10.1097/md.0000000000007840</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_5S5HFGB">Medicine</title>
		<imprint>
			<biblScope unit="volume">96</biblScope>
			<biblScope unit="issue">34</biblScope>
			<biblScope unit="page">7840</biblScope>
			<date type="published" when="2017">2017</date>
			<pubPlace>Baltimore)</pubPlace>
		</imprint>
	</monogr>
	<note type="raw_reference">Zhao Y, Li SP, Liu L, Zhang JL, Chen G. Does the choice of tariff matter? A comparison of EQ-5D-5L utility scores using Chinese, UK, and Japanese tariffs on patients with psoriasis vulgaris in Central South China. Medicine (Baltimore). 2017;96(34): e7840. doi:10.1097/MD.0000000000007840</note>
</biblStruct>

<biblStruct xml:id="b52">
	<analytic>
		<title level="a" type="main" xml:id="_RwVSF8g">Does the Dermatology Life Quality Index (DLQI) underestimate the disease-specific burden of psoriasis patients?</title>
		<author>
			<persName><forename type="first">A</forename><surname>Langenbruch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Radtke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Gutknecht</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Augustin</forename><forename type="middle">M</forename></persName>
		</author>
		<idno type="DOI">10.1111/jdv.15226</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_TJmQaBu">J Eur Acad Dermatol Venereol</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="123" to="127" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Langenbruch A, Radtke MA, Gutknecht M, Augustin M. Does the Dermatology Life Quality Index (DLQI) underestimate the disease-specific burden of psoriasis patients? J Eur Acad Dermatol Venereol. 2019;33(1):123-127. doi:10.1111/jdv.15226</note>
</biblStruct>

<biblStruct xml:id="b53">
	<analytic>
		<title level="a" type="main" xml:id="_W6U9mfx">EQ-5D health utilities: exploring ways to improve upon responsiveness in psoriasis</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">S</forename><surname>Pickard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Gooderham</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Hartz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Nicolay</surname></persName>
		</author>
		<idno type="DOI">10.1080/13696998.2016.1219359</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_BSCskzJ">J Med Econ</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="19" to="27" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Pickard AS, Gooderham M, Hartz S, Nicolay C. EQ-5D health utilities: exploring ways to improve upon responsiveness in psoriasis. J Med Econ. 2017; 20(1):19-27. doi:10.1080/13696998.2016.1219359</note>
</biblStruct>

<biblStruct xml:id="b54">
	<analytic>
		<title level="a" type="main" xml:id="_fEk8WMk">Evaluation of Skindex-16 construct validity in routinely collected psoriasis data: a retrospective analysis of the relationship between overall physician global assessment scores and Skindex-16 and measure discordance</title>
		<author>
			<persName><forename type="first">Z</forename><forename type="middle">H</forename><surname>Hopkins</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Kuceki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">L</forename><surname>Taliercio</surname></persName>
		</author>
		<idno type="DOI">10.21203/rs.3.rs-2063345/v1</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_RRcGQW9">Arch Dermatol Res</title>
		<imprint>
			<biblScope unit="volume">315</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="1151" to="1159" />
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Hopkins ZH, Kuceki G, Taliercio VL, et al. Evaluation of Skindex-16 construct validity in routinely collected psoriasis data: a retrospective analysis of the relationship between overall physician global assessment scores and Skindex-16 and measure discordance. Arch Dermatol Res. 2023;315(5):1151-1159.</note>
</biblStruct>

<biblStruct xml:id="b55">
	<analytic>
		<title level="a" type="main" xml:id="_6d8zXt7">German adaptation of the Skindex-29 questionnaire on quality of life in dermatology: validation and clinical results</title>
		<author>
			<persName><forename type="first">M</forename><surname>Augustin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Wenninger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Amon</surname></persName>
		</author>
		<idno type="DOI">10.1159/000078581</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_bvf93SP">Dermatology</title>
		<imprint>
			<biblScope unit="volume">209</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="14" to="20" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Augustin M, Wenninger K, Amon U, et al. German adaptation of the Skindex-29 questionnaire on quality of life in dermatology: validation and clinical results. Dermatology. 2004; 209(1):14-20. doi:10.1159/000078581</note>
</biblStruct>

<biblStruct xml:id="b56">
	<analytic>
		<title level="a" type="main" xml:id="_Jex6aPc">Graphic representation of illness: a novel method of measuring patients&apos; perceptions of the impact of illness</title>
		<author>
			<persName><forename type="first">S</forename><surname>Büchi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Sensky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Sharpe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Timberlake</surname></persName>
		</author>
		<idno type="DOI">10.1159/000012284</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_8qdTMGQ">Psychother Psychosom</title>
		<imprint>
			<biblScope unit="volume">67</biblScope>
			<biblScope unit="issue">4-5</biblScope>
			<biblScope unit="page" from="222" to="225" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Büchi S, Sensky T, Sharpe L, Timberlake N. Graphic representation of illness: a novel method of measuring patients&apos; perceptions of the impact of illness. Psychother Psychosom. 1998;67(4-5):222- 225. doi:10.1159/000012284</note>
</biblStruct>

<biblStruct xml:id="b57">
	<analytic>
		<title level="a" type="main" xml:id="_SRbGzFx">Health state utilities and subjective well-being among psoriasis vulgaris patients in mainland China</title>
		<author>
			<persName><forename type="first">L</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Zhao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Chen</surname></persName>
		</author>
		<idno type="DOI">10.1007/s11136-018-1819-2</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_ZhcUrvu">Qual Life Res</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="1323" to="1333" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Liu L, Li S, Zhao Y, Zhang J, Chen G. Health state utilities and subjective well-being among psoriasis vulgaris patients in mainland China. Qual Life Res. 2018;27(5):1323-1333. doi:10.1007/s11136- 018-1819-2</note>
</biblStruct>

<biblStruct xml:id="b58">
	<analytic>
		<title level="a" type="main" xml:id="_KH7UnPK">Health status and quality of life in patients with psoriasis: an Iranian cross-sectional survey</title>
		<author>
			<persName><forename type="first">M</forename><surname>Moradi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Rencz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Brodszky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Moradi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Balogh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Gulácsi</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.jval.2014.08.2147</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_WMyEzAs">Arch Iran Med</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="153" to="159" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Moradi M, Rencz F, Brodszky V, Moradi A, Balogh O, Gulácsi L. Health status and quality of life in patients with psoriasis: an Iranian cross-sectional survey. Arch Iran Med. 2015;18(3):153-159.</note>
</biblStruct>

<biblStruct xml:id="b59">
	<analytic>
		<title level="a" type="main" xml:id="_Vxb7z59">Health-related quality of life in adult atopic dermatitis and psoriatic patients matched by disease severity</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">V</forename><surname>Chernyshov</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_TRn8nDT">G Ital Dermatol Venereol</title>
		<imprint>
			<biblScope unit="volume">151</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="37" to="43" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Chernyshov PV. Health-related quality of life in adult atopic dermatitis and psoriatic patients matched by disease severity. G Ital Dermatol Venereol. 2016;151(1):37-43.</note>
</biblStruct>

<biblStruct xml:id="b60">
	<analytic>
		<title level="a" type="main" xml:id="_R39e82c">Health-related quality of life in patients with psoriasis and atopic dermatitis measured with SF-36, DLQI and a subjective measure of disease activity</title>
		<author>
			<persName><forename type="first">L</forename><surname>Lundberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Johannesson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Silverdahl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Hermansson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Lindberg</surname></persName>
		</author>
		<idno type="DOI">10.1080/000155500300012873</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_xrdZ2Z5">Acta Derm Venereol</title>
		<imprint>
			<biblScope unit="volume">80</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="430" to="434" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Lundberg L, Johannesson M, Silverdahl M, Hermansson C, Lindberg M. Health-related quality of life in patients with psoriasis and atopic dermatitis measured with SF-36, DLQI and a subjective measure of disease activity. Acta Derm Venereol. 2000;80(6):430-434. doi:10.1080/ 000155500300012873</note>
</biblStruct>

<biblStruct xml:id="b61">
	<analytic>
		<title level="a" type="main" xml:id="_MFFQt3t">How does psoriasis affect quality of life? Assessing an Ingram-regimen outpatient programme and validating the WHOQOL-100</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Skevington</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Bradshaw</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Hepplewhite</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Dawkes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">R</forename><surname>Lovell</surname></persName>
		</author>
		<idno type="DOI">10.1111/j.1365-2133.2005.07045.x</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_rnVuUNQ">Br J Dermatol</title>
		<imprint>
			<biblScope unit="volume">154</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="680" to="691" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Skevington SM, Bradshaw J, Hepplewhite A, Dawkes K, Lovell CR. How does psoriasis affect quality of life? Assessing an Ingram-regimen outpatient programme and validating the WHOQOL-100. Br J Dermatol. 2006;154(4):680-691. doi:10.1111/j.1365-2133.2005.07045.x</note>
</biblStruct>

<biblStruct xml:id="b62">
	<analytic>
		<title level="a" type="main" xml:id="_nFqrThD">Identification of psoriatic patients at risk of high quality of life impairment</title>
		<author>
			<persName><forename type="first">Sojević</forename><surname>Timotijević</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Janković</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Trajković</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename></persName>
		</author>
		<idno type="DOI">10.1111/1346-8138.12201</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_a5Fxd7m">J Dermatol</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="797" to="804" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Sojević Timotijević Z, Janković S, Trajković G, et al. Identification of psoriatic patients at risk of high quality of life impairment. J Dermatol. 2013;40 (10):797-804. doi:10.1111/1346-8138.12201</note>
</biblStruct>

<biblStruct xml:id="b63">
	<analytic>
		<title level="a" type="main" xml:id="_bDD8g7s">Impact of active and stable psoriasis on health-related quality of life: the PSO-LIFE study</title>
		<author>
			<persName><forename type="first">E</forename><surname>Daudén</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Herrera</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Puig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Sánchez-Carazo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Toribio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Perulero</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.adengl.2013.02.008</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_hY8YKEu">Actas Dermosifiliogr</title>
		<imprint>
			<biblScope unit="volume">104</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="685" to="693" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Daudén E, Herrera E, Puig L, Sánchez-Carazo JL, Toribio J, Perulero N. Impact of active and stable psoriasis on health-related quality of life: the PSO-LIFE study. Actas Dermosifiliogr. 2013;104(8): 685-693. doi:10.1016/j.adengl.2013.02.008</note>
</biblStruct>

<biblStruct xml:id="b64">
	<analytic>
		<title level="a" type="main" xml:id="_qyvZxw3">Impact of psoriasis on quality of life in Iran</title>
		<author>
			<persName><forename type="first">S</forename><surname>Aghaei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Moradi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">S</forename><surname>Ardekani</surname></persName>
		</author>
		<idno type="DOI">10.4103/0378-6323.48689</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_NnJhNTM">Indian J Dermatol Venereol Leprol</title>
		<imprint>
			<biblScope unit="volume">75</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page">220</biblScope>
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Aghaei S, Moradi A, Ardekani GS. Impact of psoriasis on quality of life in Iran. Indian J Dermatol Venereol Leprol. 2009;75(2):220. doi:10.4103/ 0378-6323.48689</note>
</biblStruct>

<biblStruct xml:id="b65">
	<analytic>
		<title level="a" type="main" xml:id="_KFfcSMr">A method for designing a patient burden questionnaire in dermatology</title>
		<author>
			<persName><forename type="first">K</forename><surname>Ezzedine</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Bennani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Shourick</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Taieb</surname></persName>
		</author>
		<idno type="DOI">10.2147/ccid.s260323</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_Gx5uGdc">Clin Cosmet Investig Dermatol</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="521" to="528" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Ezzedine K, Bennani M, Shourick J, Taieb C. A method for designing a patient burden questionnaire in dermatology. Clin Cosmet Investig Dermatol. 2020;13:521-528. doi:10.2147/CCID. S260323</note>
</biblStruct>

<biblStruct xml:id="b66">
	<analytic>
		<title level="a" type="main" xml:id="_KvrG3vj">Measurement properties of Skindex-16: a brief quality-of-life measure for patients with skin diseases</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Chren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Lasek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">P</forename><surname>Sahay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">P</forename><surname>Sands</surname></persName>
		</author>
		<idno type="DOI">10.1177/120347540100500202</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_bvuApdQ">J Cutan Med Surg</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="105" to="110" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Chren MM, Lasek RJ, Sahay AP, Sands LP. Measurement properties of Skindex-16: a brief quality-of-life measure for patients with skin diseases. J Cutan Med Surg. 2001;5(2):105-110. doi: 10.1177/120347540100500202</note>
</biblStruct>

<biblStruct xml:id="b67">
	<analytic>
		<title level="a" type="main" xml:id="_TDadAY6">Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L in psoriasis patients</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">K</forename><surname>Poór</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Rencz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Brodszky</surname></persName>
		</author>
		<idno type="DOI">10.1007/s11136-017-1699-x</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_VTpHCcf">Qual Life Res</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="3409" to="3419" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Poór AK, Rencz F, Brodszky V, et al. Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L in psoriasis patients. Qual Life Res. 2017;26(12):3409-3419. doi:10.1007/ s11136-017-1699-x</note>
</biblStruct>

<biblStruct xml:id="b68">
	<analytic>
		<title level="a" type="main" xml:id="_ckSRgq3">IDI Multipurpose Psoriasis Research on Vital Experiences (IMPROVE) Investigators. Measures of clinical severity, quality of life, and psychological distress in patients with psoriasis: a cluster analysis</title>
		<author>
			<persName><forename type="first">F</forename><surname>Sampogna</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Sera</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Abeni</surname></persName>
		</author>
		<idno type="DOI">10.1046/j.0022-202x.2003.09101.x</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_KZPVJbU">J Invest Dermatol</title>
		<imprint>
			<biblScope unit="volume">122</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="602" to="607" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Sampogna F, Sera F, Abeni D; IDI Multipurpose Psoriasis Research on Vital Experiences (IMPROVE) Investigators. Measures of clinical severity, quality of life, and psychological distress in patients with psoriasis: a cluster analysis. J Invest Dermatol. 2004;122(3):602-607. doi:10.1046/j.0022-202X. 2003.09101.x</note>
</biblStruct>

<biblStruct xml:id="b69">
	<analytic>
		<title level="a" type="main" xml:id="_7qqNHS2">Measuring health-related quality of life in patients with mild to moderate eczema and psoriasis: clinical validity, reliability and sensitivity to change of the DLQI</title>
		<author>
			<persName><forename type="first">X</forename><surname>Badia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Mascaró</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R;</forename><surname>Lozano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Cavide</forename><surname>The</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Group</forename><surname>Research</surname></persName>
		</author>
		<idno type="DOI">10.1046/j.1365-2133.1999.03112.x</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_VQb69tZ">Br J Dermatol</title>
		<imprint>
			<biblScope unit="volume">141</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="698" to="702" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Badia X, Mascaró JM, Lozano R; The Cavide Research Group. Measuring health-related quality of life in patients with mild to moderate eczema and psoriasis: clinical validity, reliability and sensitivity to change of the DLQI. Br J Dermatol. 1999;141(4): 698-702. doi:10.1046/j.1365-2133.1999.03112.x</note>
</biblStruct>

<biblStruct xml:id="b70">
	<analytic>
		<title level="a" type="main" xml:id="_7KjY3Pn">Measuring quality of life in patients with psoriasis using the Arabic version for Morocco of the Dermatology Life Quality Index</title>
		<author>
			<persName><forename type="first">I</forename><surname>Khoudri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">Z</forename><surname>Lamchahab</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Ismaili</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Senouci</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Hassam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Abouqal</surname></persName>
		</author>
		<idno type="DOI">10.1111/j.1365-4632.2011.05450.x</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_WnNKxn5">Int J Dermatol</title>
		<imprint>
			<biblScope unit="volume">52</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="795" to="802" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Khoudri I, Lamchahab FZ, Ismaili N, Senouci K, Hassam B, Abouqal R. Measuring quality of life in patients with psoriasis using the Arabic version for Morocco of the Dermatology Life Quality Index. Int J Dermatol. 2013;52(7):795-802. doi:10.1111/j. 1365-4632.2011.05450.x</note>
</biblStruct>

<biblStruct xml:id="b71">
	<analytic>
		<title level="a" type="main" xml:id="_qr8yDpj">Nail Assessment in Psoriasis and Psoriatic Arthritis (NAPPA): development and validation of a tool for assessment of nail psoriasis outcomes</title>
		<author>
			<persName><forename type="first">M</forename><surname>Augustin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Blome</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Costanzo</surname></persName>
		</author>
		<idno type="DOI">10.1111/bjd.12664</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_DXsPMGy">Br J Dermatol</title>
		<imprint>
			<biblScope unit="volume">170</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="591" to="598" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Augustin M, Blome C, Costanzo A, et al. Nail Assessment in Psoriasis and Psoriatic Arthritis (NAPPA): development and validation of a tool for assessment of nail psoriasis outcomes. Br J Dermatol. 2014;170(3):591-598. doi:10.1111/bjd.12664</note>
</biblStruct>

<biblStruct xml:id="b72">
	<analytic>
		<title level="a" type="main" xml:id="_yAduK2S">Pasi and pqol-12 score in psoriasis: is there any correlation?</title>
		<author>
			<persName><forename type="first">V</forename><surname>Shankar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Ghosh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Ghosh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Chaudhuri</surname></persName>
		</author>
		<idno type="DOI">10.4103/0019-5154.82482</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_485FxJq">Indian J Dermatol</title>
		<imprint>
			<biblScope unit="volume">56</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="287" to="289" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Shankar V, Ghosh S, Ghosh K, Chaudhuri U. Pasi and pqol-12 score in psoriasis: is there any correlation? Indian J Dermatol. 2011;56(3):287-289. doi:10.4103/0019-5154.82482</note>
</biblStruct>

<biblStruct xml:id="b73">
	<analytic>
		<title level="a" type="main" xml:id="_uryydVH">Pictorial Representation of Illness and Self Measure (PRISM): a novel visual instrument to measure quality of life in dermatological inpatients</title>
		<author>
			<persName><forename type="first">B</forename><surname>Mühleisen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Büchi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Schmidhauser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Jenewein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">E</forename><surname>French</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">F</forename><surname>Hofbauer</surname></persName>
		</author>
		<idno type="DOI">10.1001/archdermatol.2009.121?utm_campaign=articlePDF%26utm_medium=articlePDFlink%26utm_source=articlePDF%26utm_content=jamadermatol.2023.5439</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_BMurMw5">Arch Dermatol</title>
		<imprint>
			<biblScope unit="volume">145</biblScope>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page" from="774" to="780" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Mühleisen B, Büchi S, Schmidhauser S, Jenewein J, French LE, Hofbauer GF. Pictorial Representation of Illness and Self Measure (PRISM): a novel visual instrument to measure quality of life in dermatological inpatients. Arch Dermatol. 2009; 145(7):774-780. doi:10.1001/archdermatol.2009.121</note>
</biblStruct>

<biblStruct xml:id="b74">
	<analytic>
		<title level="a" type="main" xml:id="_gZV7mYh">Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment</title>
		<author>
			<persName><forename type="first">J</forename><surname>Koo</surname></persName>
		</author>
		<idno type="DOI">10.1016/s0733-8635(05)70376-4</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_FdmguE9">Dermatol Clin</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="485" to="496" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Koo J. Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Dermatol Clin. 1996;14(3):485-496. doi:10.1016/S0733-8635(05)70376-4</note>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
